Rheumatology

In contrast to TNF inhibitors for psoriatic arthritis, which seem to peak and maintain response percentages, the DISCOVER-2 Trial (McInnes et al., PMI...

4 Answers available

How do you approach selecting biologic therapy vs non-biologic DMARD (such as methotrexate) as initial therapy in patients with new RA diagnosis with significant erosive disease?

4 Answers available

When do you consider tapering tocilizumab in patients with GCA in remission?

1 Answer available

What is your approach to using medications that can cause bone marrow suppression in SLE patients who have persistent leukopenia?

3 Answers available

When do you begin antifibrotic therapy for a patient with newly diagnosed ILD that is not IPF?

Do you base the decision on FEV1, 6MWD or symptoms at initial evaluation, or progression over time?

4 Answers available

What is your approach to the workup for an underlying systemic condition in a patient presenting with retinal vasculitis?

1 Answer available

How do you decide on a steroid sparing agent for idiopathic orbital inflammation partially responsive to steroids?

1 Answer available

What is the risk of ILD recurrence in MDA5/Ro52 positive dermatomyositis following a lung transplantation?

1 Answer available

How do you interpret treatment response in the DISCOVER-2 Trial when patients were allowed to remain on up to 10mg of prednisone equivalent for disease control while on guselkumab?

In clinical practice continued steroid dependence is often seen as a reason to switch therapy and providers can be especially hesitant to use systemic...

3 Answers available

Where in the sequence of biologics would you consider guselkumab for patients with active psoriatic arthritis despite standard DMARD therapy?

Based on the results of the DISCOVER-2 Trial (McInnes et al., PMID 34719872), should guselkumab be used prior to anti-TNF therapy in these patients?

3 Answers available

How do you decide on initiation of treatment with steroids or immunomodulatory therapy in patients with statin-induced myopathy versus statin-induced autoimmune necrotizing myopathy?

In patients presenting with likely statin-induced myopathy versus statin-induced autoimmune necrotizing myopathy - how do you approach the decision re...

3 Answers available

How do you approach the use of bisphosphonates in reproductive-aged women?

1 Answer available

Despite the lack of evidence, do you utilize glucosamine and chondroitin sulfate for osteoarthritis?

2 Answers available

How long do you continue hydroxychloroquine in pediatric patients with quiescent lupus?

1 Answer available

Does romosozumab need to be followed immediately by an anti-resorptive agent to preserve BMD gains, or could you consider a drug holiday?

1 Answer available

What is your experience with using extended release intra-articular steroid preparations, such as Zilretta in patients with osteoarthritis?

2 Answers available

How do you counsel young adults with antibody-negative necrotizing myopathy on prognosis and long-term monitoring/treatment?

How do you counsel young adults with antibody-negative necrotizing myopathy on prognosis, risk of recurrence, and long-term monitoring/treatment?

1 Answer available

Would you target the same hydroxychloroquine blood level for discoid lupus compared to systemic lupus?

1 Answer available

How would you approach a patient with refractory polymyositis (elevated CK, weakness) despite MMF, IVIG, and moderate dose prednisone?

Would you consider adding tacrolimus in this situation?

2 Answers available

What workup do you do for patients who have PL-7 elevation when screening for myopathy?

2 Answers available

Is rituximab for refractory ITP contraindicated in the setting of an active COVID infection, particularly in a patient with asymptomatic COVID?

2 Answers available

When do you consider vascular imaging in patients with Raynaud's and what type of imaging modalities do you utilize?

1 Answer available

How do you mitigate the risk of renal crisis from corticosteroids in a patient with UCTD?

1 Answer available

What is your approach to refractory erosive osteoarthritis?

Significant impact on ADLs and no response to doxycycline, hydroxychloroquine, sulfasalazine or methotrexate.

2 Answers available

How do you work up patients who present with elevated myoglobin in the setting of normal creatinine kinase and exercise intolerance?

For patients who present with elevated myoglobin in the setting of normal creatinine kinase and exercise intolerance, what work up process do you typi...

1 Answer available

How do you approach the continued use of TNF inhibitors in a patient with inflammatory arthritis who develops a positive dsDNA without clinical evidence of drug-induced lupus?

2 Answers available

Is there a role for cyclophosphamide in refractory digital ischemia in patients with scleroderma?

1 Answer available

How would you approach the treatment of checkpoint inhibitor mediated temporal arteritis?

Is there role for IVIG? Would you alter the dose or time course of steroid therapy?

2 Answers available

What is the negative predictive value of a negative extended myositis panel in dermatomyositis patients?

2 Answers available

Do you feel comfortable using azathioprine for dermatomyositis in patients with cirrhosis?

For example, in the setting of cirrhosis incidentally found on imaging.

2 Answers available

How do you manage psoriatic arthritis in patients who are planning to start treatment with checkpoint inhibitors for underlying malignancy?

2 Answers available

What is your approach to workup for an underlying disorder in a patient with bilateral hip avascular necrosis?

1 Answer available

Is nailfold capillaroscopy useful for prognostication and evaluation of disease progression in MCTD/myositis patients?

1 Answer available

Do you recommend allopurinol desensitization in gout patients who develop a rash on allopurinol therapy?

2 Answers available

Would you have concerns starting an anti-TNF in RA patients with history of ITP/chronic idiopathic thrombocytopenia?

1 Answer available

How do you manage recurrent inflammatory pleural effusions in lupus pleuritis?

1 Answer available

Is there a role for IVIG in the treatment of active morphea refractory to immunosuppressive agents?

1 Answer available

Would you consider the use of rilonacept to treat refractory pericarditis in lupus?

4 Answers available

Do you escalate treatment for reactive lymphadenopathy in an otherwise stable and asymptomatic patient with lupus?

(assuming that the malignancy evaluation has been completed and the lymphadenopathy is confirmed to be reactive)

1 Answer available

If you have clinical suspicion for a paraneoplastic process (e.g. dermatomyositis or pemphigus), what work-up do you pursue?

1 Answer available

Do you recommend routine genetic screening (i.e., periodic fever panel) in a pediatric patient where you strongly suspect a periodic fever syndrome?

2 Answers available

Would you consider the use of low-dose naltrexone in patients with fibromyalgia and/or type 2 lupus symptoms?

4 Answers available

Would you avoid the entire class of bisphosphonates if a patient develops an allergic reaction, or would you consider the use of an alternative bisphosphonate?

2 Answers available

How do you approach a patient on anti-TNF with positive Quantiferon(previously negative) with negative chest x-ray and no symptoms?

3 Answers available

How do you interpret elevations in antiphospholipid antibodies that are lower than Sapporo criteria?

(e.g. beta 2 glycoprotein IgM > 20 but <40)

2 Answers available

How do you approach CV risk assessment in RA patients when RA itself is associated with some degree of increased CV risk at baseline?

Recent articles regarding the use of JAK-Inhibition in RA have suggested to avoid in patients with increased CV risk. However, RA itself is cons...

2 Answers available

Have you had experience using the new Echolight technology to measure bone density?

2 Answers available

How do you approach adding colchicine to a patient who is on a stable statin regimen?

2 Answers available

At what point do you recommend muscle biopsy in the workup for myositis?

1 Answer available

Do you use conventional DMARDs aside from methotrexate to prevent anti-drug antibody development for patients on infliximab?

3 Answers available

When do you reach for tacrolimus in patients with myositis?

2 Answers available

How important do you feel HLAB51 testing is in diagnosing Behcet's disease?

In your experience, are there specific disease manifestations in which HLAB51 is particularly helpful?

1 Answer available

How do you manage inflammatory back pain when X-rays and MRI show no evidence of sacroiliitis?

Is an MRI necessary to diagnose non-radiographic axial spondyloarthritis?

1 Answer available

How do you use hydroxychloroquine in patients with lupus nephritis on hemodialysis or peritoneal dialysis?

2 Answers available

What role do you see for JAK inhibitors in RA treatment strategies given the data we now have regarding CV and cancer outcomes?

For example, would it be appropriate to consider JAK inhibitor therapy as preferable to TNF-alpha inhibitor in patients with heart failure with reduce...

4 Answers available

What is the role of non-prednisone oral glucocorticoids in the management of systemic rheumatologic disease?

Such as oral methylprednisolone, dexamethasone, prednisolone, etc.

1 Answer available

When do you consider DMARD therapy in patients with persistent oligoarticular JIA who continue to flare in adulthood?

1 Answer available

Would you recommend that a patient with stable coronary artery disease and well-controlled RA on a JAK inhibitor continue on their current therapy?

2 Answers available

What is your approach to treating tophaceous gout in patients whose uric acid is below 5 prior to initiating uric acid lowering therapy?

1 Answer available

Would you consider using avacopan in PR3+ mononeuritis multiplex without other systemic involvement?

1 Answer available

Do you still plan to offer tofacitinib to RA patients over 65 if they have one or more additional CV risk factors?

2 Answers available

How do you counsel patients regarding the cardiovascular and cancer risks associated with tofacitinib?

2 Answers available

How do you approach relapsing ANCA-associated vasculitis in a patient who has already undergone kidney transplant?

1 Answer available

How do you approach biologic initiation in patients with inflammatory arthritis and repeatedly indeterminate Quantiferon?

2 Answers available

Is there a role for immunosuppression in addition to standard PAH therapy in the management of pulmonary hypertension associated with primary Sjogrens syndrome?

Assuming other non CTD related causes for PAH have been excluded

1 Answer available

How do you clinically distinguish between group I and group III PH in patients with CTD-ILD?

1 Answer available

What do you recommend for fertility preservation in pediatric patients with impending cyclophosphamide use for treatment of a rheumatic disease?

2 Answers available

How do you manage anti-Mi-2 positive dermatomyositis with predominantly cutaneous manifestations?

1 Answer available

Do you utilize soluble IL-2 receptor or ACE levels as serum biomarkers to monitor disease activity in pulmonary sarcoidosis?

1 Answer available

How do you approach urate-lowering therapy in patients with advanced chronic kidney disease?

What doses of allopurinol do you use, and how frequently do you titrate the dose?

1 Answer available

In what patients would you consider adjunctive IVIG for Sjogren's-related neuropathy?

2 Answers available

Do you continue methotrexate while starting TNFi therapy in patients with refractory pulmonary sarcoidosis?

3 Answers available

Would you anticoagulate recurrent venous thromboembolism in a patient with Ehlers Danlos syndrome?

How would the approach differ if the patient had a significant bleeding phenotype vs only minor bruising and mucosal bleeding?

1 Answer available

How do you manage a patient with giant cell arteritis treated with weekly tocilizumab and low dose glucocorticoid who develops sudden vision loss?

2 Answers available

How do you treat patients with sarcoid who have persistent symptoms after an initial 6 week course of corticosteroids?

3 Answers available

Is there a role for medications, beyond treatment for concomitant psychiatric disorders, in the management of pediatric amplified musculoskeletal pain syndrome?

1 Answer available

How would you interpret a positive dsDNA in a patient with a negative ANA performed via indirect immunofluorescence?

4 Answers available

What is the preferred approach to treating poorly-controlled RA in the setting of active hepatitis B undergoing anti-viral therapy?

1 Answer available

Which medications have the lowest risk of tuberculosis reactivation in patients with uncertain tuberculosis history and active rheumatologic disease?

2 Answers available

Do you consider the use of antifibrotics at presentation in patients with a radiographic UIP pattern of pulmonary fibrosis in the presence of positive serologies without any symptoms of CTD (ie, fulfilling a possible diagnosis of IPAF) who have not yet demonstrated evidence of a progressive phenotype?

1 Answer available

Would you consider using teriparatide beyond a cumulative maximum of two years now that the black box warning regarding osteosarcoma has been removed?

1 Answer available

How do you approach the use of parathyroid hormone-related protein analog drugs in the setting of prior external beam radiation?

If you avoid parathyroid hormone-related protein analog drugs in patients with prior external beam radiation, what data is this based on?

1 Answer available

Can giant cell arteritis present with a partial cranial neuropathy?

3 Answers available

What is the difference between Multisystem Inflammatory Syndrome in Adults (MIS-A) and MAS/HLH?

1 Answer available

Do you recommend the use of dexamethasone and anakinra as upfront treatment in a pediatric patient with secondary HLH (nonrheumatic) who is too ill to tolerate etoposide?

This type of etoposide sparing therapy has been previously described in a case series at https://pubmed.ncbi.nlm.nih.gov/32725881/

2 Answers available

How do you approach treating cutaneous PAN?

Other than inflammatory markers and following symptoms/exam, do you need any other specific monitoring for progression to systemic disease?

1 Answer available

Would you consider using DOACs in a young patient with SLE and Libman-Sacks endocarditis, who is negative for APS?

1 Answer available

Do you recommend using IL-1/IL-6 inhibitors in COVID-19 multisystem inflammatory syndrome in adults (MIS-A)?

1 Answer available

Do you generally recommend low dose aspirin for patients with giant cell arteritis?

2 Answers available

Would you offer palliative radiation for painful bone metastases in a patient with scleroderma?

1 Answer available

Would you discontinue anticoagulation in patients with antiphospholipid antibody syndrome, who have a remote history of thrombotic events and are now negative for pathogenic antiphospholipid antibodies?

Would the answer differ if the index event was arterial vs venous?

3 Answers available

How would you approach treating patients with RA refractory to cDMARDs and a prior history of MALT lymphoma?

1 Answer available

Does calcinosis appear differently in patients with dermatomyositis compared to systemic sclerosis?

1 Answer available

Why do we not typically see features of rhabdomyolysis or acute kidney injury with idiopathic inflammatory myopathies?

1 Answer available

Do you routinely monitor the QTc when adding voclosporin to hydroxychloroquine in a patient with lupus nephritis?

1 Answer available

How do you approach DMARD therapy in patients with rheumatoid arthritis and chronic hepatitis B?

Hepatitis screening labs revealing Hep B ag and core positivity with positive PCR

2 Answers available

When would you consider rituximab as induction therapy in IgG4-related disease?

4 Answers available

How do you approach the work up for patients with fibromyalgia and hypermobility?

When do you refer to genetics? Does your approach change if they have an additional finding such as mitral valve prolapse or a prolapsed bladder/uteru...

3 Answers available

Would you have any hesitation to use belimumab in a patient with IgA deficiency?

1 Answer available

Do you treat fibromyalgia in your practice or do you refer back to PCP after ruling out autoimmune inflammatory pathology?

3 Answers available

Do you repeat antiphospholipid antibody testing in a patient that previously met criteria for APLS?

If so, how long after diagnosis do you do so?

1 Answer available

What kinds of dental work do you particularly worry about and try to avoid in patients on bisphosphonates?

2 Answers available

Would you still consider durvalumab consolidation after definitive chemoradiation for patients with Stage III NSCLC who are on stable weekly methotrexate dosing for psoriasis/psoriatic arthritis?

1 Answer available

When would you suspect metabolic myopathy and what is your approach to initial workup?

2 Answers available

Do you have any hesitations for combining belimumab with any of the DMARDs in patients with SLE/RA overlap?

2 Answers available

How do you differentiate a lupus flare versus drug-induced lupus in patients with SLE on a drug associated with DILE?

2 Answers available

Is active rheumatoid arthritis (RA) a contraindication to hypofractionated breast irradiation?

How does a diagnosis of active RA inform your treatment approach for patients with breast cancer, if at all?

4 Answers available

How do you utilize methotrexate and/or hydroxychloroquine in the setting of limited scleroderma/CREST?

1 Answer available

Would you start a TNF-I for seronegative non-erosive RA in a patient with positive ANA and sun sensitivity without other SLE features?

1 Answer available

Is there any utility in checking HLA-B*5801 in our Black and Asian patients who are already tolerating allopurinol?

1 Answer available

Would you intensify therapy in IgG4 related disease based solely on a persistently significantly elevated IgG4 level when all disease manifestations and inflammatory markers have normalized?

1 Answer available

What is the role of x-ray of the cervical or lumbar spine in patients presenting with radicular symptoms?

I teach my students/residents that they should hardly ever get routine X-rays in patients presenting with radicular symptoms. MRI far better for seein...

4 Answers available

Do you recommend routine use of Evusheld for pre-exposure prophylaxis for patients on immunosuppression?

Does treatment with B-cell depletion and/or negative anti-spike antibody status despite COVID mRNA vaccination influence your decision?

1 Answer available

What is your approach to treatment for a patient with progressive ILD (UIP pattern) with high titer RF but no articular symptoms?

1 Answer available

In what circumstances do you pursue labial salivary gland biopsy in an asymptomatic patient with high titer ANA and positive SSA?

How do you risk stratify and monitor such patient for disease progression or organ involvement?

2 Answers available

Would you advise a patient with quiescent vasculitis who flared with the first Covid mRNA vaccine to obtain an additional dose?

Would you suggest switching to a viral vector vaccine, such as J&J?

2 Answers available

Do you avoid dupilumab (IL-4 inhibition) for severe asthma in patients already taking a biologic agent for RA?

1 Answer available

What is the differential for a patient with unilateral arm swelling, MRI with muscle edema, and markedly elevated CPK?

There is no history of trauma or substance abuse.

2 Answers available

What is your approach to severe discoid lupus refractory to conventional topical and systemic therapies?

(Refractory to mycophenolate, azathioprine, and methotrexate. UpToDate suggests thalidomide or IVIG with mixed efficacy, while there are some case rep...

4 Answers available

What is your approach for gout flare prophylaxis in patients with diabetes and advanced CKD?

Preference for low dose steroids vs attempting colchicine?

1 Answer available

How do you treat anti-HMGCoA myopathy?

3 Answers available

What bDMARD would you choose for a patient with RA with high infection risk and inadequate response to cDMARDs?

Infection risk being primarily chronic venous stasis ulcers

1 Answer available

In your experience, is there an association between interstitial cystitis and systemic lupus erythematosus?

2 Answers available

Is there a role for regular hepatitis and TB screening in patients on chronic immunosuppressive therapy in the absence of new risk factors or exposures?

1 Answer available

Should we recommend the COVID-19 booster vaccine to patients who had a DVT or any other complications such as hemolytic anemia or thrombocytopenia from prior vaccine doses?

2 Answers available

Do you find IgA isotypes of anti-beta2-glycoprotein antibodies and anticardiolipin antibodies to be clinically useful in the evaluation for APS?

Do you routinely check IgA anticardiolipin and beta-2 glycoprotein antibody IgA in your practice? And how would a positive result change your manageme...

2 Answers available

How do you counsel patients about the risk of osteonecrosis of the jaw with anabolic agents such as teriparatide or romosozumab ?

Would you hold these agents in the setting of invasive dental procedures?

1 Answer available

How do you treat lupus-associated small fiber neuropathy?

1 Answer available

How do you manage drug-induced thrombocytopenia when the implicated drug is essential?

e.g. DITP from eptifibatide after a cardiac intervention

1 Answer available

What is your approach to initial assessment of disease extent in patients with Behcet's disease?

How does this vary from continued disease monitoring?

1 Answer available

What has been your experience using apremilast to treat mild to moderate psoriatic arthritis not controlled with NSAIDs?

1 Answer available

Are there any known contraindications for IL-23 use in patients with psoriatic arthritis and CKD or ESRD?

1 Answer available

What are your recommendations for a patient with metastatic non-mutated lung adenocarcinoma who previously had headaches responsive to prednisone but with negative temporal artery biopsy for GCA?

For medical oncologists, would you offer a PD-1/L1 inhibitor? For other subspecialties, how would you counsel the oncologist regarding the risk of usi...

1 Answer available

How do you approach a potential drug holiday in a patient with osteoporosis who has had improvement in BMD after several years of denosumab therapy?

1 Answer available

What lab markers are helpful for monitoring polymyalgia rheumatica patients on tocilizumab?

Since tocilizumab is known to normalize ESR/CRP, are there any markers/blood tests that may be helpful to check for PMR patients with question of exac...

1 Answer available

In the absence of lung disease, do you prefer methotrexate or mycophenolate mofetil in the initial treatment of cutaneous-only manifestations in systemic sclerosis?

2 Answers available

Is nailfold capillaroscopy useful for prognostication and evaluation of disease progression in scleroderma patients?

1 Answer available

When tapering moderate to high doses of long term steroids do you routinely monitor for adrenal insufficiency?

Do you attempt to taper fully or maintain at a low dose?

2 Answers available

What do you view as reasonable alternatives to cyclophosphamide in the treatment of neuropsychiatric lupus?

4 Answers available

What features help distinguish thyroid myopathy from immune checkpoint inhibitor-associated myopathy?

1 Answer available

How do you treat multisystem sarcoidosis refractory to methotrexate, humira, and remicade?

2 Answers available

How do you think about biologic use in patients with underlying HIV infection?

2 Answers available

How would you approach evaluation and treatment of a patient on pembrolizumab therapy who presents with symmetric, proximal, upper extremity and lower extremity painful weakness without an elevated CK?

1 Answer available

How do you approach the use of endothelin receptor antagonists in patients with scleroderma renal crisis and hypertension refractory to maximum ACE inhibition and calcium channel blockers?

1 Answer available

What is your approach to treating dermatomyositis patients with pruritus recalcitrant to oral and topical steroids?

2 Answers available

Do you hold tocilizumab for patients who are diagnosed with Covid and are with mild to moderate symptoms or non-hospitalized?

1 Answer available

What strategy do you use to determine the appropriate timing to resume osteoporosis therapy after a drug holiday?

2 Answers available

Do you ever consider treatment outside of the peripartum period in a patient with a history of obstetric APS?

i.e. obstretric APS without thrombosis or SLE

2 Answers available

What is your approach to a patient with well-controlled seropositive RA on abatacept who develops melanoma?

Would you change the treatment to rituxan or continue orencia with regular dermatology follow up?

1 Answer available

How would you approach new-onset large vessel vasculitis in a young patient with Crohn's disease?

3 Answers available

Is a biopsy of either skin or muscle always indicated in the diagnosis of dermatomyositis?

1 Answer available

Would you have any concerns about starting an anti-TNF in RF and anti-CCP positive RA patients who also have high titer ANA?

Is there an increased drug induced lupus risk?

2 Answers available

For patients with scleroderma at high risk of renal crisis, would you feel comfortable giving corticosteroids as pre-medication for rituximab?

1 Answer available

How do you approach the workup of a patient with incidentally found pachymeningitis?

1 Answer available

Do you recommend EMG/NCS in all patients with clinical findings of carpal tunnel syndrome?

4 Answers available

At what point is a skin biopsy indicated in patients with neuropathy?

1 Answer available

Do you always perform temporal artery biopsy in patients with positive inflammatory markers and high clinical suspicion of GCA?

2 Answers available

Is either ESR or CRP more sensitive or specific for the diagnosis of GCA?

Additionally, what is the current role for temporal artery ultrasound in workup for GCA?

3 Answers available

How would you treat corneal melt (in the absence of peripheral arthritis) in rheumatoid arthritis?

What immunosuppression and dosing do you typically use?

1 Answer available

What is your approach to evaluation of underlying autoimmune disease in patients with bilateral scleromalacia?

1 Answer available

How do you treat post-IVIG headache that is not responsive to Tylenol or NSAIDs?

Specifically, how do you treat the delayed headache, not the headache that develops during the infusion where pre-hydration and slowing down the rate ...

4 Answers available

How do you treat celiac disease associated inflammatory arthritis refractory to gluten free diet?

1 Answer available

What is the utility in repeating a temporal ultrasound (US) in a previously US diagnosed positive GCA patient who has received treatment and is presenting with recurrent GCA symptoms?

1 Answer available

How do you approach the management of immunosuppression in patients with lupus nephritis that go on to dialysis?

3 Answers available

Is it ever appropriate to reduce urate lowering therapy dose due to very low urate levels?

Are there implications of reducing urate too much?

1 Answer available

How would you approach asymptomatic hepatic sarcoid?

Multiple lesions on PET

1 Answer available

Would you consider continuing a biologic for difficult to control autoimmune disease in a patient with a recent diagnosis of a surgically curable solid malignancy?

Would you favor the use of any particular biologics over others?

1 Answer available

What is your approach to treating severe manifestations of neuropsychiatric SLE in the setting of concomitant infection?

1 Answer available

Is there a role for immunosuppression in patients with triple positive antiphospholipid antibodies who do not meet the clinical criteria for APS?

2 Answers available

What particular pre-operative considerations should we consider for SLE patients undergoing elective surgery?

1 Answer available

How do you approach DMARD therapy in a patient with lupus and recurrent pericarditis?

1 Answer available

How do you approach the use of commercial testing such as AVISE CTD in clinical practice?

1 Answer available

How will you utilize newly FDA approved anifrolumab for SLE in your practice?

2 Answers available

Do you measure drug levels (particularly hydroxychloroquine or mycophenolate) in your lupus patients?

Several speakers at ACR 2021 commented on the important role of drug levels in the management of these patients and cautioned against adding medicatio...

1 Answer available

Do you find 14.3.3 eta or vectra DA helpful in clinical practice?

1 Answer available

Is there a role for prednisolone over prednisone in rheumatic patients with hepatic impairment?

1 Answer available

In a patient with inflammatory orbital disease without a discrete mass to biopsy and recent bisphosphonate use, how much additional workup would you do if basic labs, urine studies, ANCA serologies, thyroid studies, chest imaging (to r/out sarcoid) are normal, before concluding that the process is likely secondary to bisphosphonate use?

Without a discrete mass to biopsy, is there any utility of any blind biopsies to rule out IgG4 related disease, infectious or neoplastic process?

1 Answer available

How do you manage a patient with inclusion body myositis?

Is there a role for immunomodulatory therapy?

2 Answers available

How do you approach immunosuppressive therapy in lupus-associated pulmonary arterial hypertension?

2 Answers available

What is your approach to a patient with normal LFTS and high titer auto-antibodies suggestive of autoimmune hepatitis?

Is a liver biopsy ever helpful?

1 Answer available

When a patient with a preexisting rheumatic disease and on immunotherapy begins to flare, how do you decide if this is an underlying rheumatic disease activity versus an immunotherapy related adverse event?

How do you decide if it may be safe to continue immunotherapy?

1 Answer available

Is there any experience of using sarilumab instead of tocilizumab for steroid sparing effect in GCA during national tocilizumab shortage?

1 Answer available

Would you consider use of an oral bisphosphonate (such as alendronate liquid) in a patient with eosinophilic esophagitis?

1 Answer available

How would you approach a patient with gastric MALT lymphoma who has CREST syndrome?

Would chemotherapy be preferred over RT?

2 Answers available

How would you approach osteoporosis management in a patient who fractures while on denosumab therapy?

Would you consider keeping the patient on denosumab or would switch to an anabolic agent?

1 Answer available

Do you screen for HLA-B*5801 prior to starting allopurinol in patients of backgrounds other than Asian or African-American?

Specifically in patients of Vietnamese background? An association has been shown between HLA-B*5801 and the risk of allopurinol hypersensitivity react...

1 Answer available

Would you use voclosporin or belimumab as adjunctive therapy for treatment of lupus nephritis?

Especially given the recent FDA approval of voclosporin, how should we think about the use of this medication for LN?

3 Answers available

Given the "LDL Paradox", in which RA patients with the highest levels of inflammation can have ultra-low levels of LDL (<70), how do you approach initiation of statin therapy in these patients?

Dr. Charles-Schoeman presented data at ACR 21 showing that, paradoxically, there is a U-shaped relationship between inflammation and LDL levels in pat...

1 Answer available

Would you consider use of belimumab in a patient with SLE with recurrent anterior uveitis who failed other treatment options?

Patient failed topical ocular therapies, methotrexate, azathioprine

2 Answers available

How do you clinically distinguish between cutaneous lupus with photosensitivity and polymorphic light eruption-like reactions?

1 Answer available

What is the role for angiography in the workup of digital ischemia?

Do you obtain vascular imaging routinely in these cases, and if so, do you use cross-sectional or invasive angiography?

1 Answer available

Is there a role for antibody testing to confirm vaccine response for patients on rituximab after COVID-19 vaccination?

1 Answer available

How would you approach treatment for fulminant RA-associated ILD?

Would you discontinue Methotrexate and TNF inhibitors even if previously no side effects from these medications, and would you consider Cyclophosphami...

1 Answer available

When would you consider checking JC virus prior to initiating biologic therapy?

1 Answer available

What immunosuppressive agents would be available to patients with a history of melanoma?

Would you use immunosuppression in patients several years after curative treatment for melanoma?

1 Answer available

How do you approach prophylaxis against glucocorticoid-induced osteoporosis in patients with end-stage renal disease on dialysis?

1 Answer available

What is your preferred approach for patients with anti-phospholipid syndrome with recurrent thrombosis on coumadin and LMWH?

1 Answer available

How would you approach definitive treatment of intermediate-risk prostate cancer with baseline severe (AUA >25) urinary dysfunction and severe rheumatoid arthritis?

Would your answer change for favorable vs unfavorable intermediate risk disease?

1 Answer available

How will you use REGEN-COV (casirivimab/imdevimab-monoclonal antibody treatment recently approved under EUA as post-exposure prophylaxis for Covid) in rheumatic patients on immunosuppressive therapy?

Would you consider this for patients on B-cell depleting therapies or more broadly for other immunosuppressive agents?

2 Answers available

What is your management approach for patients with Adult Onset Still's who are planning pregnancy?

1 Answer available

Do you routinely obtain a chest x-ray prior to initiating anti-TNF or other biologic therapy?

Does Quantiferon gold replace the need for baseline chest x-ray screen?

1 Answer available

What was the rationale for abrupt discontinuation of etanercept rather than gradual tapering in the SEAM-RA trial?

The ACR 2021 RA Guidelines suggest the gradual tapering approach is preferable.

2 Answers available

Was the methotrexate dose reduced over time in the combination therapy or methotrexate monotherapy groups in the SEAM-RA trial?

Giving "rescue therapy" to patients in the combination group implies that there is room to escalate to the dose at enrollment.

1 Answer available

Are the results of the SEAM-RA trial generalizable to other TNF inhibitors given the differences in immunogenicity?

Withdrawal of methotrexate may lead to more disease flares and lack of recoverability with other TNF inhibitors.

1 Answer available

Were the patients enrolled in the SEAM-RA trial prior methotrexate monotherapy non-responders?

Usual clinical practice is to add TNFi once methotrexate monotherapy has failed. If this is the case in these patients, it would seem to increase the ...

1 Answer available

Have you seen rheumatoid nodules or RA-ILD in patients with seronegative RA?

While classically described as seen in seropositive patients, have they been reported in seronegative RA?

2 Answers available

What are your recommendations regarding methotrexate usage in patients with persistent chest CT changes post COVID pneumonia?

Would you have a different opinion based on whether it is a new therapy or an existing and previously well-tolerated therapy for the patient?

2 Answers available

How do you approach the use of steroids for active muscle disease in patients with scleroderma-myositis overlap syndromes?

1 Answer available

What suspected myositis manifestations drive you to start empiric therapy before the work-up is complete?

Myositis specific antibodies and pathology results often take weeks to result. In which cases do you start therapy before the diagnosis is solid...

1 Answer available

How would you treat a poorly controlled seronegative RA patient who is steroid dependent and is on azathioprine for autoimmune hepatitis?

2 Answers available

What is your approach to a patient with positive antiphospholipid antibodies who otherwise do not meet clinical criteria for APS?

What if the patient is triple-positive or has continued seropositivity on repeat lab testing? What is the appropriate interval of monitoring and does ...

3 Answers available

How do you counsel patients regarding the cardiovascular risk of febuxostat?

1 Answer available

Do you recommend COVID vaccination in patients with antiphospholipid antibody positivity or other prothrombotic states not on anti-coagulation?

1 Answer available

What is your approach to managing sclerosing mesenteritis (mesenteric panniculitis)?

Do you have a preferred initial immunosuppressive regimen?

2 Answers available

How do you diagnose and treat patients who develop uveitis while on bisphosphonate therapy for osteoporosis?

Are there specific features that suggest drug-induced uveitis versus de novo uveitis?

1 Answer available

What is your steroid-sparing agent of choice to treat GCA given the current tocilizumab shortage?

Thoughts on sarilumab vs methotrexate, or just treat with steroids alone

1 Answer available

What is your approach to checking serum vWF antigen levels in adult patients with CNS vasculitis for monitoring disease activity?

Small study in pediatric PACNS have evaluated this as a potential marker (Cellucci et al., PMID 22740622)

1 Answer available

How do you interpret DXA results in cases where there is discordance between normal hip and spine BMD with abnormal one-third radius BMD?

2 Answers available

Do you consider low-dose aspirin for primary thromboprophylaxis in patients with high-risk antiphospholipid antibody profiles?

While low-dose aspirin for primary thrombosis prevention in aPL without APS is not typically recommended outside cardiovascular prevention guidelines ...

1 Answer available

How are you timing the third dose of the COVID-19 mRNA vaccine in patients on rituximab?

1 Answer available

How long would you treat with antimycobacterials before starting biologic DMARD in a patient with latent TB and active rheumatoid arthritis?

1 Answer available

Would you pursue temporal artery biopsy in patients with PMR who develop cranial GCA symptoms and have been on PMR dose steroids for one year?

1 Answer available

What is your approach to a patient with rheumatoid arthritis and moderate disease activity on 25 mg of PO methotrexate?

Do you switch to SQ MTX, or is it best to add tx, such as a TNFi?

1 Answer available

How do you approach infused prostacyclin therapy for critical digital ischemia?

What factors go into choosing the right patient and determining length of therapy?

1 Answer available

What is your approach for disease activity monitoring in patients with sarcoidosis?

1 Answer available

In which patients with autoimmune or inflammatory conditions are you recommending a 3rd dose of the mRNA COVID vaccine?

2 Answers available

Is it ever reasonable to switch to a different TNFi as opposed to switching to an agent in a different class in a case of TNFi induced lupus or psoriasis?

In other words, do we think of TNFi induced lupus and TNFi induced psoriasis as a drug effect or a class effect?

1 Answer available

How do you approach treatment of osteoporosis in patients with CKD who develop a fragility fracture while on denosumab?

1 Answer available

What is your approach to differentiating SLE flare in pregnancy vs pre-eclampsia?

1 Answer available

Would you have concerns using azathioprine in NXP-2 or TIF-1 gamma positive dermatomyositis patients due to higher risk of malignancy?

1 Answer available

How long do you continue steroid-sparing agents such as tocilizumab for GCA once the disease is in remission off steroids?

1 Answer available

What criteria do you use on echocardiogram and PFT to determine who needs further evaluation for CTD-associated pulmonary hypertension?

1 Answer available

How do you approach NSAID use in patients on SSRIs?

Do you avoid due to the increased risk of GI adverse events?

1 Answer available

What disease activity measures do you find helpful in clinical practice for psoriatic arthritis/peripheral spondyloarthritis?

1 Answer available

What indicators do you use to identify patients with CTD-ILD who do not have potential to improve from continued immunosuppressive therapy?

Do you use imaging (fibrosis vs. pneumonitis), PFTs, duration of prior immunosuppressive therapy?

1 Answer available

How do you approach treatment of vasculitis in a sickle cell disease patient?

There are multiple difficulties that could be seen: steroids can precipitate a sickle cell crisis, vasculitis and sickle cell can produce similar clin...

1 Answer available

Do you recommend stopping TNF inhibitors during the third trimester of pregnancy?

How does disease activity and certolizumab vs other TNFi affect this decision?

1 Answer available

What is your differential for a patient presenting with multiple digits affected by flexor tenosynovitis, dupuytren's, and no evidence of peripheral inflammatory arthritis?

1 Answer available

What studies do you find helpful to determine if an axial spondyloarthritis patient presenting late in the disease course with significant irreversible joint damage may benefit from immunosuppression?

1 Answer available

How do you approach folate supplementation for methotrexate-related side effects?

3 Answers available

What is your approach to a patient with incidental radiographic findings of sacroiliitis without clinical inflammatory back pain?

2 Answers available

Do you advise patients to hold DMARDs for conditions such as psoriasis or rheumatoid arthritis while actively undergoing radiation treatment?

Does it depend on the DMARD type (biologic, targeted synthetic, or conventional synthetic)?

2 Answers available

How do you approach monitoring for lymphoproliferative disease in Sjogren's patients?

2 Answers available

What is your approach to monitoring lipids in patients with rheumatic diseases such as RA and SLE and do you have a lower threshold to start lipid lowering agents compared to the general population?

2 Answers available

What are your thoughts on use of 14-3-3 serum levels in rheumatoid arthritis in conjunction with RF and ACPA?

1 Answer available

Is there a role for starting an anabolic agent in a patient that developed an atypical femoral fracture while on denosumab sooner than 6 months after the last denosumab dose?

Is there a role for earlier use of anabolic agents to promote bone healing in patients that develop AFFs?

2 Answers available

Would you consider single agent TKI for patient with metastatic renal cell carcinoma who developed biopsy proven giant cell arteritis days after starting immunotherapy?

Would active vasculitis present a contraindication to therapy?

1 Answer available

Are there any specific circumstances when you would consider the use of immunosuppression for DISH?

There is some emerging evidence that there is an inflammatory component.

1 Answer available

What do you use for treatment induction in pure class V lupus nephritis with nephrotic-range proteinuria when MMF is contraindicated?

2 Answers available

Is there a role for measuring serum mycophenolate mofetil levels (or its active metabolite) in the management of lupus nephritis?

1 Answer available

Does the presence of ANCA antibodies in patients with newly diagnosed lupus nephritis alter your approach to management?

1 Answer available

What is your preferred regimen for remission induction and maintenance in EGPA with cardiac involvement?

1 Answer available

How do you approach patients with ANCA vasculitis who had partial response, but continue to have disease activity on q 6 month maintenance rituximab and remain on steroids?

Would you change rituximab maintenance dose or schedule?

1 Answer available

How do you determine when to transition off pegloticase to other uric acid lowering therapies?

1 Answer available

How would you approach localized lymphadenopathy in a patient with lupus whose symptoms are otherwise well-controlled?

2 Answers available

What is your approach to long-Covid/post-Covid syndrome in your practice?

2 Answers available

How do you approach screening for inflammatory bowel disease prior to starting IL-17 inhibitors?

1 Answer available

How do you choose between oral and IV cyclophosphamide for the treatment of ANCA-associated vasculitis?

1 Answer available

How would you counsel a patient who is interested in using supplements (such as fish oil or turmeric) as an adjunct to treatment of inflammatory arthritis?

3 Answers available

How do you manage steroid-refractory immune checkpoint inhibitor induced pneumonitis?

3 Answers available

In which clinical scenarios is relying on the urine protein-to-creatinine ratio as a measure of proteinuria unreliable, and interpretations should be made looking at urine protein and urine creatinine separately?

1 Answer available

How do you approach monitoring of patients found to have a positive anti-dsDNA antibody without other clinical evidence of SLE?

1 Answer available

How do you approach the treatment of eosinophilic fasciitis refractory to glucocorticoids and methotrexate?

1 Answer available

Should TNF inhibitors be held in patients undergoing radiation therapy?

Is there a risk of increased radioresistance or secondary malignancy (or conversely, toxicity) for patients on TNF inhibitors...

1 Answer available

What is your methotrexate initiation strategy in DMARD-naive RA patients?

Specifically: starting dose, rapidity of up-titration, frequency of lab monitoring, frequency of office visits, and timing of assessment for treatment...

2 Answers available

What is your approach for treating mononeuritis multiplex in patients with ANCA vasculitis?

Specifically, do you reach for Rituximab or cyclophosphamide?

1 Answer available

What immunosuppressive agents aside from steroids would you use to treat bronchiolitis obliterans in a patient with long-standing seropositive RA?

1 Answer available

How do you approach the management of SSc-ILD in a patient on immune checkpoint therapy?

1 Answer available

How do you approach treatment for arthritis associated with multicentric reticulohistiocytosis?

1 Answer available

How do you approach transaminitis with use of allopurinol in gout?

Do you rechallenge with lower dose? What is your tolerance for mild persistent transaminitis?

1 Answer available

Would you consider using a TNFi in a patient with a family history of demyelinating disease, in the absence of a personal history?

2 Answers available

How do you approach a patient with IgG4-related disease who has failed rituximab and mycophenolate and continues to rely on high-dose steroids?

The case I am considering involves a patient with biopsy-proven fibrosing dacryoadenitis.

1 Answer available

How do you approach management of patients with inflammatory arthritis who are asymptomatic but develop radiographic progression?

1 Answer available

Would you start tocilizumab in a patient with temporal arteritis and cirrhosis?

1 Answer available

Is there a role for to the use of transient elastography (FibroScan) to monitor liver fibrosis in rheumatic patients on long-term methotrexate?

1 Answer available

How would you advise patients with known stable autoimmune thrombocytopenia regarding the Ad26.COV2.S (Johnson & Johnson/Janssen) vaccine?

1 Answer available

How do you approach the use of low-dose aspirin for primary prevention in non-pregnant patients with SLE and positive aPL antibodies, without clinical criteria for APS?

Do you follow the 2019 EULAR Guidelines that SLE patients with asymptomatic, positive aPL should be on low-dose ASA?

1 Answer available

How do you transition to an anabolic agent in a patient who develops an atypical fracture while on denosumab?

1 Answer available

What therapies have you had the most success with for calcinosis cutis in dermatomyositis patients?

1 Answer available

What is your threshold for number of alcoholic drinks per week before reconsidering prescribing methotrexate/leflunomide?

1 Answer available

How do you approach the use of biologics in patients with a history of Guillain-Barre syndrome?

1 Answer available

How do you advise patients who had autoimmune diseases "triggered" by COVID infections on getting COVID vaccination?

E.g., inflammatory polyarthritis or inflammatory myopathy with onset within 2 weeks of documented COVID infection

1 Answer available

What is your strategy to prevent and treat constipation in patients initiating or receiving opioids?

What non-pharmacological interventions do you recommend? Do you routinely prescribe prophylactic laxatives to patients initiating opioids? How do you ...

3 Answers available

Should the use of avacopan be limited to those patients at increased risk of steroid toxicity given the anticipated high cost of this medication?

ADVOCATE trial

1 Answer available

Are there scenarios where you send additional antibodies beyond anti-centromere, Scl-70, and RNA polymerase III in suspected scleroderma patients?

1 Answer available

What is your approach to managing abnormal lipids in a patient on tocilizumab?

1 Answer available

How do you treat an AAV patient with recurrent bronchial stenosis that has not responded to rituximab induction therapy and dilatations?

1 Answer available

What is your approach to a patient with an isolated positive rheumatoid factor, negative anti-CCP antibody, and no clinical or imaging evidence of rheumatoid arthritis?

3 Answers available

Do you eventually stop urate-lowering therapy in gout patients with CKD who start hemodialysis?

1 Answer available

How would you manage an active rheumatoid arthritis patient on suppressive antibiotic therapy for ocular HSV who has abnormal liver function tests?

1 Answer available

How do you counsel patients on JAK inhibitors about the risk of venous thromboembolism, MACE, and cancer?

1 Answer available

Do you approach therapy differently for patients with a diagnosis of osteoporosis based on a fragility fracture rather than based on bone mineral density on DXA (assuming no secondary causes of osteoporosis)?

1 Answer available

Do you check pertussis serologies when sending labs for antiphospholipid syndrome?

2 Answers available

How useful are anti-ribosomal P antibodies in the evaluation for SLE psychosis?

1 Answer available

Are there any concerns about using nintedanib in a patient with progressive fibrosing ILD on background mycophenolate?

1 Answer available

When would you use tocilizumab to treat Takayasu's?

1 Answer available

Do you recommend checking anti-drug antibodies for patients on TNF inhibitors?

If so, how would positive levels guide your management?

2 Answers available

How do you approach therapy for severe osteoporosis after an initial 12 months of romosozumab?

1 Answer available

What is your initial treatment of choice in patients with RA and associated interstitial lung disease?

1 Answer available

When is it necessary to monitor the QTc interval in patients on hydroxychloroquine?

2 Answers available

Are there features of a nerve biopsy that help distinguish late nerve damage from vasculitis versus from a demyelinating disease?

1 Answer available

How do you approach the treatment of inflammatory polyarthritis in patients with myelodysplastic syndromes?

2 Answers available

What aspects on history and physical exam could help differentiate genetic muscular dystrophy from immune-mediated myopathy?

1 Answer available

When have you found Dual-Energy CT most useful in evaluating for gout?

3 Answers available

What would be your next step in management of a dermatomyositis patient on hydroxychloroquine and methotrexate whose skin is still active?

Muscle disease is quiescent and no other manifestations such as ILD

1 Answer available

How do you treat CTD-associated organizing pneumonia?

How is your approach to treatment different than other ILD patterns such as NSIP? Does treatment response vary based on underlying CTD?

2 Answers available

How do you approach immunosuppression targeting skin thickening in scleroderma after the initial three years of onset?

(Skin thickening in the absence of visceral disease)

1 Answer available

Do you continue methotrexate in inflammatory arthritis patients who develop squamous cell skin cancer while on that therapy?

1 Answer available

How should the results of the ADVOCATE trial be applied in AAV patients who receive rituximab induction and maintenance therapy?

In the ADVOCATE trial, patients were not re-dosed with rituximab.

1 Answer available

Are there particular subsets of AAV patients in which avacopan is more effective?

E.g., MPO vs PR3, newly diagnosed vs relapsed, renal involvement. Acknowledge that the ADVOCATE study was not powered to detect these differences, but...

1 Answer available

How do you approach peri-operative management of anti-resorptive therapies such as denosumab in patients undergoing joint replacement?

Does denosumab effect knee replacement or hip replacement? Should replacement occur right before or after injection?

1 Answer available

What agent would you choose for a patient who needs osteoporosis therapy after a bisphosphonate holiday?

2 Answers available

How will you use tocilizumab in the treatment algorithm for SSc-ILD, given its recent FDA approval?

1 Answer available

Do you treat HIV/AIDS-associated CNS vasculitis with antiretrovirals alone or in combination with steroids?

1 Answer available

Would you offer lung SBRT to a medically inoperable patient with systemic lupus erythematosus or other connective tissue disorders if well controlled?

If so, do you take any additional precautions with planning?

1 Answer available

How would you recommend dosing the MMR or other live vaccines for patients with rheumatoid arthritis on immunosuppressive medications such as anti-TNF alpha therapy?

For example, healthcare workers who require these vaccines for employment

1 Answer available

How do you monitor response to treatment in patients with mononeuritis multiplex secondary to vasculitis?

Given the slow recovery of nerve damage, what would you expect to see on a repeat EMG after treatment? Continued denervation or just sequelae of past ...

1 Answer available

Is it okay to use medications associated with drug-induced lupus in patients with SLE?

1 Answer available

How would you approach refractory gangrenous Raynaud's secondary to type one cryoglobulins?

What if the patient has MGUS? Do patients with type 1 cryoglobulins need a bone marrow biopsy as part of the work up?

1 Answer available

What do you use to treat uveitis refractory to conventional synthetic DMARDs and TNF inhibitors?

Are IL-17 or IL-23 inhibitors helpful?

5 Answers available

How do you treat Raynaud's in patients with baseline low blood pressure?

1 Answer available

Are there any therapeutic options for cauda equina syndrome secondary to dural ectasia in end-stage ankylosing spondylitis?

1 Answer available

Do you image the spine in addition to the sacroiliac joints when you suspect axial spondyloarthritis?

Can axSpA affect the spine without affecting the sacroiliac joints?

1 Answer available

How do you treat RA in patients with pulmonary mycobacterium avium complex (MAC) infections?

1 Answer available

How would you approach a patient with MPO-positive isolated peripheral nerve vasculitis?

How would you label such a patient? Would you treat differently if they have poor functional status?

2 Answers available

Would you continue TNFi for inflammatory arthritis if the patient develops a solid organ malignancy while on that therapy?

1 Answer available

How do you approach dosage changes of allopurinol as a patient's GFR decreases over time?

2 Answers available

Are there particular concerns related to the use of B-cell depletion therapies such as rituximab for rheumatic disease during the COVID-19 pandemic?

1 Answer available

Should all patients with suspected giant cell arteritis get a PET scan to look for large vessel disease?

3 Answers available

How would you manage methotrexate therapy in an active rheumatoid arthritis patient undergoing treatment for latent TB with rifampin?

Do you stop methotrexate or adjust the dose?

1 Answer available

Do you recommend the use of contrast to identify sacroiliitis on MRI?

2 Answers available

How do you approach the evaluation of patients referred for chronic lyme disease and counsel patients regarding this entity?

1 Answer available

How do you approach treatment of rheumatoid arthritis in a patient with an active hematologic malignancy (such as leukemia or lymphoma) after methotrexate failure?

Does your management change if there is renal involvement of the malignancy?

2 Answers available

When would you recommended restarting biologic medications in an active RA patient after treatment with monoclonal antibodies, convalescent plasma or antiviral medications for a COVID-19 infection?

1 Answer available

How would you treat uveitis in a patient with a history of cutaneous T cell lymphoma?

Patient was previously well controlled on methotrexate, which was discontinued during cancer treatment.

1 Answer available

What is the utility of MRI for identifying disease activity in myositis patients when physical exam and labs are inconclusive?

3 Answers available

Do you extrapolate from uveitis treatment pathways when managing other inflammatory eye conditions such as atypical serpiginous choroiditis?

2 Answers available

Are there any situations in which you would consider starting steroid-sparing agents at the outset for patients with scleritis without any evidence of systemic rheumatic disease?

2 Answers available

What is your approach to treatment for MDA5 dermatomyositis patients with rapidly progressive ILD?

Cyclophosphamide/tacrolimus and Rituximab have been used in conjunction with steroids in case series.

1 Answer available

Is there a role for G-CSF treatment for SLE patients with persistent neutropenia?

1 Answer available

Is there a role for anti-IL6 therapy in SSc-associated ILD?

1 Answer available

Do you find addition of quinacrine to methotrexate or mycophenolate helpful in treatment of refractory CADM?

1 Answer available

What treatment options are available for patients with spondyloarthritis who develop biologic-induced psoriasis?

1 Answer available

Are there AAV patients for whom you would consider combination therapy with cyclophosphamide and rituximab?

1 Answer available

How do you manage arthralgias with subclinical synovitis seen on US or MRI?

1 Answer available

What is your approach to treatment of lupus peritonitis?

1 Answer available

Are you recommending tocilizumab for any COVID-19 patients?

Current guidelines do not support its use, but the EMPACTA trial suggests it may be effective in a subpopulation of patients.

1 Answer available

Do you switch to certolizumab in RA patients who are doing well on other TNFis and planning to become pregnant?

1 Answer available

Do you escalate treatment in patients with myositis who achieve clinical remission but continue to have elevated CPK?

2 Answers available

Is there a role for measuring hydroxychloroquine blood levels in clinical practice?

If so, are there specific patient populations for which you would use this metric?

1 Answer available

What is your threshold for pursuing bone marrow biopsy in a lupus patient with cytopenias?

2 Answers available

What is considered an adequate treatment period to assess response of AAV induction therapy with rituximab or cyclophosphamide?

1 Answer available

How do you approach a patient found to have a coronary lesion suggestive of vasculitis on coronary CT?

1 Answer available

Which EGPA patients are most likely to benefit from treatment with anti-IL-5 agents such as mepolizumab?

1 Answer available

What is the biologic of choice in a patient with RA and myasthenia gravis?

1 Answer available

How do you approach anticoagulation in patients with catastrophic antiphospholipid syndrome and thrombocytopenia?

1 Answer available

How does a history of splenectomy alter how you counsel patients on the infection risk of TNF inhibitors or other biologics?

1 Answer available

Are you recommending the mRNA COVID-19 vaccines to your patients with immune mediated inflammatory diseases?

5 Answers available

What steroid sparing agent do you use for treatment of cardiac sarcoidosis?

Does the type of cardiac involvement impact this choice?

2 Answers available

Is there evidence that either ASDAS or BASDAI is superior for measuring clinical outcomes in axial spondyloarthritis?

1 Answer available

For which rituximab infusion reaction symptoms do you consider it safe to re-challenge in the office with adjusted rates and pre-medications?

1 Answer available

Is a comprehensive physical exam with vital signs warranted for routine follow-up visits in well-controlled uncomplicated RA patients?

Reduced requirements for documentation by CMS in 2021 with respect to billing and coding have raised new questions about what aspects of physician exa...

1 Answer available

Would you use an IL-17 inhibitor for a psoriatic arthritis patient with inactive inflammatory bowel disease?

1 Answer available

Do you assess baseline salivary gland function before starting treatment in patients with Sjogren's syndrome?

If so, what test do you use in clinical practice?

1 Answer available

Should MTX be avoided in RA patients with asymptomatic lung nodules?

If so, what would be an ideal DMARD in this setting?

1 Answer available

What are specific treatment considerations for dactylitis- or enthesitis-predominant AxSpa/PsA?

1 Answer available

Do you recommend shingles vaccine to all immunosuppressed patients under the age of 50 y.o.?

1 Answer available

What are the benefits of sending HLA B27 genotype over HLA B27 antigen when evaluating for spondyloarthritis?

2 Answers available

Do you correct the synovial fluid white blood cell count for red blood cells, and if so, is there a rough approximation/equation you use?

2 Answers available

How do you approach patients with overlapping features of PMR and seronegative RA?

1 Answer available

Should venous thrombosis in a patient with Behcet syndrome be treated with both immunosuppression and anticoagulation?

1 Answer available

How do you screen for colon cancer in patients with Behcet syndrome with colonic involvement?

1 Answer available

What is the biologic of choice in a patient with RA and history of non-melanoma skin cancer?

2 Answers available

How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?

2 Answers available

How does the presence of myositis alter your interpretation of cardiac enzymes when evaluating acute chest pain?

i.e., Troponin I, Troponin T, and CK-MB

1 Answer available

What is your approach to treating refractory thrombocytopenia in lupus?

2 Answers available

In what situations do you consider platelet-rich plasma injections in patients with osteoarthritis?

1 Answer available

In gout, do MSU crystals form only in tissue, or are there circulating microcrystals of MSU within blood vessels?

If so, does this have clinical significance?

2 Answers available

At what point in GCA management do you typically introduce tocilizumab?

2 Answers available

Is there a role for PCSK9 inhibitors in patients with statin-associated immune mediated necrotizing myopathy?

1 Answer available

Is it safe to use statins in IIM patients if HMGCR antibodies are negative?

1 Answer available

Do you recommend medical therapy for extensive atraumatic osteonecrosis of the femoral head to mitigate pain or prevent femoral head collapse?

1 Answer available

Which immunosuppressed patients with SLE would benefit from antibiotic prophylaxis to prevent pneumocystis pneumonia?

1 Answer available

Would you hold all immunosuppressive medications for the first month of LTBI treatment, or just biologics?

1 Answer available

Which ANCA vasculitis patients are better candidates for cyclophosphamide rather than rituximab?

2 Answers available

How do you manage incidentally identified chemotherapy-associated aortitis/large vessel vasculitis?

1 Answer available

Would you use an anti-IL 17 over an anti-TNFa as your first line biologic in psoriatic arthritis?

Have the SPIRIT H2H and EXCEED data changed your practice?

1 Answer available

Do you recommend getting a muscle biopsy in a patient with suspected IMNM with statin exposure, weakness, elevated CK, and positive HMGCR antibody?

2 Answers available

Are there any new treatments for erosive osteoarthritis of the hands?

1 Answer available

How long do you wait for response to corticosteroids and conventional synthetic DMARDs before considering IVIG in patients with HMGCR antibody positive IMNM?

1 Answer available

Is there a role for monitoring serum ANCAs to assess ANCA associated vasculitis disease activity?

2 Answers available

Is it ever appropriate to use hydroxychloroquine temporarily in higher doses (more than 5mg/kg) to control lupus activity such as skin manifestations?

1 Answer available

Is it appropriate to consider biologic therapy for treatment of RA in a patient with non-small cell lung carcinoma treated with radiation therapy, who has ongoing active synovitis uncontrolled by conventional DMARDs?

1 Answer available

How do you interpret a high positive RNP in the setting of a negative ANA and negative sm/RNP?

To my understanding, sm/RNP should also be positive in this situation (and one would assume a positive ANA as well)

1 Answer available

How does the presence of nonalcoholic fatty liver disease (NAFLD) impact your choice of csDMARD for RA?

1 Answer available

Is there an increased risk of COVID-19 in patients on immunosuppressants?

1 Answer available

How do you counsel Takayasu patients on their prognosis?

2 Answers available

Do you monitor RS3PE patients for GCA with the same vigilance that you do in PMR patients?

1 Answer available

What is the safest approach to treating refractory RA in the setting of an active solid organ malignancy?

Prior therapies include MTX, abatacept, rituximab

1 Answer available

How would you attempt to determine the etiology of intracranial hemorrhage in a patient with newly diagnosed lupus and an active viral infection?

1 Answer available

Which patients may benefit from eculizumab in refractory APS?

2 Answers available

Do you use leflunomide in rheumatoid arthritis patients on hemodialysis?

If so, would you adjust the dose?

1 Answer available

What is your first choice contraceptive agent for women with SLE?

How do you counsel these patients about hormonal agents?

1 Answer available

How does your treatment algorithm differ for drug-induced ANCA vasculitis compared to non drug-induced ANCA vasculitis in cases with severe/organ-threatening manifestations?

1 Answer available

What agents can you use for treatment induction besides rituximab in cryoglobulinemic vasculitis (without hepatitis)?

1 Answer available

Do you avoid any specific biologic therapies in HIV positive patients?

1 Answer available

What is your inflammatory arthritis differential when a patient presents with unilateral TMJ synovitis?

2 Answers available

What is your approach to screening for cardiac involvement in patients with myositis and how does the finding of cardiac involvement change your management?

1 Answer available

Should JAK inhibitors and anti-IL6 medications be avoided in patients with known diverticulosis?

2 Answers available

Should tuberculosis screening be performed before beginning methotrexate for treatment of rheumatoid arthritis?

1 Answer available

Are there certain subsets of ANCA vasculitis patients for whom you would consider life long maintenance therapy?

2 Answers available

What is the typical work-up completed to rule out other conditions prior to making a diagnosis of fibromyalgia (other than history and physical exam)?

3 Answers available

Is it okay to use belimumab to treat SLE in a patient who has a history of lymphoma and is on a Bruton's tyrosine kinase inhibitor (such as ibrutinib)?

1 Answer available

What are examples of rheumatology quality measures that are both clinically meaningful and can be captured accurately and efficiently?

1 Answer available

Is there a role for the VECTRA or other multi-biomarker tests in evaluating rheumatoid arthritis disease activity?

1 Answer available

Do you think there is a role for belimumab in treating lupus nephritis and if so, in which patients would you considering adding it on?

Did the recently published BLISS-LN trial change your practice?

2 Answers available

How do you screen rheumatoid arthritis patients for lung disease (modality, frequency, patient selection)?

1 Answer available

Which steroid-sparing agent do you prefer to treat multi-organ Sweet's syndrome?

1 Answer available

How do you manage post-menopausal osteoporosis in a patient with stable bone density and no fractures after three years of holiday after giving zoledronic acid?

1 Answer available

Is there any role for direct oral anticoagulants in the treatment of antiphospholipid syndrome?

What if this was "triple-negative" antiphospholipid syndrome?

2 Answers available

Is it ever appropriate to initiate a higher initial dose of allopurinol (such as 300mg daily) than is typically recommended in gout patients at low risk of allopurinol hypersensitivity syndrome and severe hyperuricemia?

2 Answers available

What is your first treatment of choice in patients with dermatomyositis sine myositis?

1 Answer available

For which subset(s) of APS patients do you recommend an INR of 3 or higher?

1 Answer available

How do you assess transaminitis in a patient with sarcoidosis with known liver involvement being treated with methotrexate?

1 Answer available

How do you manage osteopenia, osteoporosis and calcium / Vit D supplementation in a patient with calcinosis?

1 Answer available

How do you treat small fiber neuropathy associated with rheumatic conditions like Sjogren’s syndrome?

1 Answer available

Do you follow patients with elevated ESR/CRP if their work-up for rheumatologic etiology is unrevealing and no other cause is identified?

2 Answers available

What are the most effective therapies for CPPD with a "pseudo-RA" pattern?

1 Answer available

What is the preferred DMARD in active spondyloarthropathy with psoriasis and sacroiliitis features in the setting of treated hepatitis C with negative viral load?

In patients refractory to NSAIDs and sulfasalazine

1 Answer available

Is romosozumab an option in a patient who has completed 2 years of teriparatide therapy and has a fracture while on denosumab?

1 Answer available

Does serologic activity (e.g., high titer dsDNA, low complements) without clinical disease activity in a pregnant lupus patient affect maternal or fetal outcomes?

2 Answers available

How do you screen dermatomyositis patients for malignancy if they have a high risk antibody profile (NXP-2/TIF1gamma positive) and their initial screen is negative?

1 Answer available

Do you continue hydroxychloroquine in lupus patients who develop cardiomyopathy?

1 Answer available

Should gonadotropin-releasing hormone (GnRH) agonists be offered to all women of reproductive age about to undergo treatment with cyclophosphamide?

2 Answers available

When is a biopsy necessary to diagnose relapsing polychondritis?

1 Answer available

What is your approach to bladder cancer surveillance in patients who have received cyclophosphamide?

1 Answer available

In what situations do you check for HIV status in your workup for inflammatory arthritis?

1 Answer available

Is it safe to treat checkpoint inhibitor-induced arthritis with methotrexate or biologics?

1 Answer available

What would you use to treat polymyositis refractory to high dose steroids, methotrexate, mycophenolate, IVIG, and cyclophosphamide?

1 Answer available

What would be your differential for a wrist monoarthritis in an elderly female with erosions on MRI after less than 3 months of symptoms?

1 Answer available

What is your approach to dental prophylaxis for patients on biologics?

1 Answer available

What are some strategies for radiographically differentiating between erosions secondary to erosive osteoarthritis versus psoriatic arthritis involving the DIP joints?

1 Answer available

How long do you continue IVIG for myositis patients in remission on that therapy?

1 Answer available

What's the best treatment for calcinosis universalis in a scleroderma patient?

1 Answer available

When treating patients with low bone mineral density, when/how do you monitor bone turnover markers (NTX, CTX, etc)?

1 Answer available

What do you use to treat a GCA patient refractory to methotrexate who responded but had adverse effects with both tocilizumab and sarilumab?

1 Answer available

What steroid-sparing agent would you use for treatment of neurosarcoidosis with leptomeningeal and parenchymal involvement?

1 Answer available

Should methotrexate be categorically avoided in RA patients with COPD or RA-ILD?

1 Answer available

How do you manage calcium and vitamin D supplementation in patients with sarcoidosis on chronic steroids?

1 Answer available

What is your work up and management for patients who develop neuropathy on a TNF inhibitor?

1 Answer available

What clinical factors do you use to determine timing of on-demand dosing of rituximab in ANCA vasculitis maintenance therapy?

1 Answer available

Do you recommend on-demand versus fixed-schedule dosing for rituximab maintenance in ANCA vasculitis?

If you use both, how do you decide which to use for a particular patient?

2 Answers available

Would you consider starting IVIG as initial steroid-sparing agent instead of azathioprine/methotrexate in a patient with inflammatory myopathy, high Jo-1, weakness with severe dysphagia and without skin involvement or ILD?

1 Answer available

Do you have any suggestions about how to improve rheumatology training in internal medicine residency programs?

Due to the shortage of rheumatologists, primary care physicians may need to manage some rheumatologic issues.

1 Answer available

How do steroids and/or DMARDs affect biopsy results if a renal biopsy for suspected lupus nephritis is delayed?

1 Answer available

Would you consider an osteoporosis medication in a pre-menopausal/young patient with a low Z score and an ongoing risk factor for secondary osteoporosis such as chronic antiepileptic treatment?

1 Answer available

How do you interpret granulomatous features on a muscle biopsy?

1 Answer available

How do you manage patients who are Hepatitis B core antibody positive/surface antigen negative and starting a biologic DMARD (other than rituximab)?

1 Answer available

Is there a role for tocilizumab in treatment of polymyalgia rheumatica in patients who do not have features of giant cell arteritis or rheumatoid arthritis?

1 Answer available

Would you avoid the use of a TNF inhibitors in patients with a remote history of melanoma, including those with ocular melanoma?

1 Answer available

Are there any clinical situations in which checking for anti-chromatin antibodies is helpful?

1 Answer available

How do you manage severe vaginal dryness and vulvodynia refractory to topical lubricants in patients with Sjogren's syndrome?

1 Answer available

Are subcutaneous RA therapies less effective in obese patients?

1 Answer available

Do you use precision medicine tools (such as RNA testing, PRISM-RA) in clinical practice before starting a TNF inhibitor for RA?

https://www.prismra.com

2 Answers available

How do you manage severe Raynaud's phenomenon with ulceration in scleroderma patients that is refractory to oral agents (CCBs, PDEis, ARBs, and ERAs)?

2 Answers available

Do you choose rituximab or calcineurin inhibitors for patients with class IV/V lupus nephritis who are refractory to standard of care therapies?

1 Answer available

Is chronic major salivary gland enlargement in a patient with Sjogren's an indication for immune-modulating therapy such as hydroxychloroquine or methotrexate?

1 Answer available

Are there any features that help differentiate Sjogren's-related CNS demyelinating plaques from multiple sclerosis in a patient with primary Sjogren's syndrome?

1 Answer available

How do you counsel patients who ask if there are any dietary modifications they can make to help control their autoimmune disease?

1 Answer available

Is there a minimum work-up necessary in patients with an ANA greater than 1:160 and no clinical symptoms suggestive of lupus (i.e., specific antibodies, UA)?

2 Answers available

How do you differentiate between axial psoriatic arthritis and axial spondylitis with psoriasis, and is it important to distinguish between these two conditions from a prognostic and treatment perspective?

1 Answer available

How do you counsel patients who ask you about trying oral or topical formulations of medical marijuana for pain related to arthritis or fibromyalgia?

1 Answer available

What baseline work-up do you do for patients with suspected palindromic rheumatism?

1 Answer available

Is it okay to use COX-2 selective NSAIDs in patients with IBD-associated arthritis when the IBD is in remission?

1 Answer available

What is the role of nintedanib in the treatment of SSc-ILD?

The SENSCIS trial was published in 2019 on efficacy of this agent. However, it's not clear where this should be in the treatment algorithm: Monot...

2 Answers available

Do you use hydroxychloroquine for prevention of neonatal lupus in patients with a positive SSA who are planning on becoming pregnant?

1 Answer available

In which osteoporosis patients would you consider starting with anabolic therapy over antiresorptive therapy?

1 Answer available

In patients with knee osteoarthritis, do you recommend the use of hyaluronate injections if it is available and affordable for the patient?

1 Answer available

When do you use tacrolimus in patients with myositis-related interstitial lung disease?

1 Answer available

Is there a subset of ANCA vasculitis patients for which you would try plasma exchange?

1 Answer available

When suspecting a diagnosis of complex regional pain syndrome (or reflex sympathetic dystrophy), what workup should be done to confirm or exclude it?

1 Answer available

What agent do you try next in patients with myositis-related interstitial lung disease who are refractory to mycophenolate mofetil and azathioprine?

1 Answer available

Would you re-challenge patients who have had a TNF-associated paradoxical adverse event (such as inflammatory bowel disease) with a different TNF inhibitor?

1 Answer available

What is your treatment algorithm for RS3PE?

1 Answer available

Is there a role for ultrasound in assessing for "clinically silent" inflammatory arthritis prior to tapering DMARD therapy?

1 Answer available

What baseline work-up or "staging" do you do in patients with a new diagnosis of Sjogren's (i.e., PFT, cryoglobulins, complement, RF, UA)?

1 Answer available

When do you stop immunosuppressants in patients with GPA?

1 Answer available

Which myositis patients are good candidates for IVIG?

3 Answers available

In the treatment of lupus nephritis, which patients may benefit from the use of rituximab or other B-cell depleting agents during induction?

1 Answer available

What is your next step in patients with polymyositis without interstitial lung disease who are refractory to methotrexate?

1 Answer available

Do you regularly do bone density testing to screen for osteoporosis in men with rheumatoid arthritis without any other risk factors?

2 Answers available

Should patients be screened for hepatitis B/C prior to starting a conventional synthetic DMARD such as methotrexate?

1 Answer available

When is it appropriate to refer a systemic sclerosis patient for bone marrow transplant evaluation?

2 Answers available

What do you try in patients with IBD-related spondyloarthritis with predominantly axial symptoms who are refractory to TNF inhibitors?

1 Answer available

Would you avoid radiation in a patient with breast cancer with active skin lupus?

In a patient with early stage breast cancer that would otherwise require radiation, would you recommend treatment if the patient has active skin lupus...

1 Answer available

In light of promising results of hydroxychloroquine in COVID-19, should we consider using it prophylactically in cancer patients, especially if immunocompromised?

Acknowledging that there is no time for good trials yet in this setting

1 Answer available

Is your approach to managing immune related adverse events altered at all in light of COVID-19?

2 Answers available

Would you offer lung SBRT for an individual with rheumatoid arthritis?

Also, how would you handle immune modulators for rheumatoid arthritis during their treatment?

1 Answer available

How do you approach further treatment of patients who develop grade 2-3 immune colitis from nivolumab/ipilimumab prior to completion of the 4 ipilimumab doses?

Do you re-challenge with nivolumab alone, change from nivo 1/ipi 3 to nivo 3/ipi 1 upon re-challenge, or stop immunotherapy altogether if grade 3?&nbs...

1 Answer available

Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?

1 Answer available

Is there a period of time after which you would not resume ICI after a patient has had an irAE and required a prolonged steroid taper?

1 Answer available

Would the need for infliximab/MTX/nonsteroidals to control initial irAE affect your decision to rechallenge these patients with ICI?

1 Answer available

Would you resume biologic treatments such as TNF blockers in patients with symptomatic autoimmune conditions who are in remission from their cancers?

How about those with metastatic disease eager to maintain quality of life? Do you risk progression of disease if the TNF blocker is re-started?

2 Answers available

How do you approach post operative radiation therapy to someone with head and neck cancer who has high risk of local recurrence who also has scleroderma?

Is there any literature on the safety of giving radiation to patients with scleroderma in H&N setting?

1 Answer available

How does the presence of active rheumatoid arthritis on rituxan impact your decision to proceed with prostate radiation?

Would you require the rituxan to be held prior to radiation? Would this matter if it was in the post-prostatectomy setting?

1 Answer available

How do you identify immunotherapy-related pneumonitis vs. radiation pneumonitis in a patient status post chemoradiation receiving consolidation immunotherapy?

Is IO related pneumonitis in the radiation field or more diffuse?

1 Answer available

Does the presence of a connective tissue disorder such as lupus or scleroderma modify your radiation dose or technique for prostate cancer?

2 Answers available

How would the presence of active rheumatoid arthritis on methotrexate impact your choice of fractionation for a patient with prostate cancer?

1 Answer available

How do you counsel an early stage breast cancer patient with lupus regarding decisions on radiation?

3 Answers available

In which patients with stage IV NSCLC and PD-L1 TPS >50% plus concomitant autoimmune disease is it considered safe to give immune checkpoint blockers?

1 Answer available

Is chronic methotrexate for rheumatoid arthritis a contraindication for prostate brachytherapy?

Are there any other medications, outside of anticoagulation, that would be considered absolute or relative contraindications?

2 Answers available

Should methotrexate be stopped prior to radiation therapy if a patient has rheumatoid arthritis?

1 Answer available

Is hypofractionation ever appropriate in women with early stage breast cancer and latent lupus who have never experienced skin symptoms in their lifetime?

Do you always stick with a conventional fracionation, or in some cases, are you comfortable hypofractionating? Do you ever use a wait and see approach...

1 Answer available

Do you use immune checkpoint inhibitors in NSCLC patients with pre-existing, well-controlled autoimmune disease?

Does the type of autoimmune disease (ex IBD, rheumatoid arthritis, interstitial lung disease) matter?

1 Answer available

Do you consider APBI a reasonable alternative to mastectomy for women with early stage breast cancer and collagen vascular diseases?

Do you put more weight on specific CVDs such as scleroderma as contraindications for any RT?

1 Answer available

How do you manage patients with early stage breast cancer with autoimmune disorders such as rheumatoid arthritis and collagen vascular disorders?

Do you have any concern for increased toxicity when you treat a patient with radiation therapy who has an autoimmune disorder? (hypofractiationation v...

1 Answer available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997-07

Irradiation in the setting of collagen vascular disease: acute and late complications.

Brachytherapy, 2011

The use of adjuvant high-dose-rate breast brachytherapy in patients with collagen vascular disease: a collaborative experience.

Brachytherapy, 2011

Partial breast irradiation in a patient with bilateral breast cancers and CREST syndrome.

JAMA Netw Open, 2021 Feb 01

Assessment of Toxic Effects Associated With Dose-Fractionated Radiotherapy Among Patients With Cancer and Comorbid Collagen Vascular Disease.

Annals of internal medicine, 2018-01-16

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.

Radiation oncology (London, England), 2012-02-16

Acute and late toxicities of radiotherapy for patients with discoid lupus erythematosus: a retrospective case-control study.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2004

Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-03

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

The New England journal of medicine, 2015-07-16

Expert Opin Drug Saf,

Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.

Cancer,

Acute and late reactions to radiation therapy in patients with collagen vascular diseases.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-10

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

J Immunother Cancer, 2019 Aug 22

Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events.

Journal for immunotherapy of cancer, 2017-11-21

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Cancer management and research, 2017

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.

Lancet Oncol., 2020 Mar 03

Risk of COVID-19 for patients with cancer.

Lancet, 2020 Feb 07

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Medicine (Baltimore),

The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Annals of the rheumatic diseases, 2017-08

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.

Lancet (London, England), 2018-12-01

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.

Arthritis Rheumatol, 2019 Oct

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Lancet, 2019 Nov 12

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.

Cochrane Database Syst Rev, 2014 Oct 23

Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.

Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers.

, 2016 Aug 30

Treatment of clinically amyopathic dermatomyositis in adults: a systematic review.

RMD open, 2015

EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide.

The New England journal of medicine, 2018-01-04

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Arthritis and rheumatism, 2012-04

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Ann Rheum Dis, 2013 Jun 05

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

Arthritis Rheumatol, 2019 Jan

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Ann. Rheum. Dis., 2019 Sep 28

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.

Lancet,

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.

Journal of psoriasis and psoriatic arthritis, 2019-04

TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management.

Arthritis and rheumatism, 2005-09

Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.

Arthritis & rheumatology (Hoboken, N.J.), 2015-05

Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus.

Lupus,

Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.

Best Pract Res Clin Obstet Gynaecol, 2019 Nov 13

Ovarian protection with gonadotropin-releasing hormone agonists during cyclophosphamide therapy in systemic lupus erythematosus.

Semin. Arthritis Rheum., 2020 Mar 19

RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs.

Arthritis Rheumatol, 2016 Jan

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Arthritis Rheumatol, 2017 Aug

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.

N. Engl. J. Med., 2019 May 20

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

The Lancet. Respiratory medicine, 2016-09

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

The New England journal of medicine, 2006-06-22

Cyclophosphamide versus placebo in scleroderma lung disease.

The journal of pain : official journal of the American Pain Society, 2019-06

AAPT Diagnostic Criteria for Fibromyalgia.

Arthritis care & research, 2019-03

Diagnosing Fibromyalgia as a Disease, an Illness, a State, or a Trait?

J. Rheumatol.,

Do Rheumatologists Need More Clues to Diagnose Fibromyalgia?

Current opinion in rheumatology, 2015-05

Current approaches to osteoporosis treatment.

Am J Med, 2012 Nov 20

Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

Clin J Pain,

Imaging in early posttraumatic complex regional pain syndrome: a comparison of diagnostic methods.

Arthritis & rheumatology (Hoboken, N.J.), 2016-05

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.

Rheumatology (Oxford),

Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?

Rheumatology (Oxford),

Axial disease in psoriatic arthritis.

Clin. Exp. Rheumatol., 2016 Dec 13

Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis.

Lancet, 2015 Oct 01

Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.

J Rheumatol Suppl,

GRAPPA 2018 Project Report.

Nat Rev Rheumatol,

Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison.

Rheumatology (Oxford),

Treatment guidelines in psoriatic arthritis.

Ann Rheum Dis, 2015 Dec 07

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.

J. Am. Coll. Cardiol.,

Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers.

Annals of the rheumatic diseases, 1999-04

Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers.

Arthritis Care Res (Hoboken),

Biopsy-Proven Small-Fiber Neuropathy in Primary Sjögren's Syndrome: Neuropathic Pain Characteristics, Autoantibody Findings, and Histopathologic Features.

Pain, 2020 May 18

Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials.

J. Rheumatol., 2019 Jan 15

Position Statement: A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases.

Arthritis and rheumatism, 1982-11

The 1982 revised criteria for the classification of systemic lupus erythematosus.

Arthritis and rheumatism, 2012-08

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

, 2019 Aug 06

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Arthritis Rheum.,

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Rheumatology (Oxford), 2020 Feb 11

Vaginal dryness in primary Sjögren's syndrome: a histopathological case-control study.

Multiple sclerosis (Houndmills, Basingstoke, England), 2014-01

Limited utility of current MRI criteria for distinguishing multiple sclerosis from common mimickers: primary and secondary CNS vasculitis, lupus and Sjogren's syndrome.

Ann. Neurol., 2018 Feb 15

Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies.

Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica.

Clin. Rheumatol., 2017 Aug 18

Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.

Archives of internal medicine, 2008-09-22

Methotrexate is not associated with progression of interstitial lung disease in rheumatoid arthritis.

Arthritis and rheumatism, 2010-06

Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study.

Arthritis Care Res (Hoboken), 2017 Aug

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.

Ann. Rheum. Dis., 2018 Apr 25

Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).

Ann. Rheum. Dis., 2017 May 25

Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.

Ann. Rheum. Dis., 2018 May 03

Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.

J Med Imaging Radiat Oncol,

Gull-wing deformity: Osteoarthritis.

J Ultrason, 2016 Mar 29

Diagnostic imaging of psoriatic arthritis. Part I: etiopathogenesis, classifications and radiographic features.

Neurology, 2016 Nov 16

Treatment of neurosarcoidosis: A comparative study of methotrexate and mycophenolate mofetil.

Clin. Chest Med., 2015 Sep 26

Neurosarcoidosis.

Clin. Exp. Rheumatol., 2013 Dec 09

Anti-TNF-α therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2016-04

Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS).

Blood, 2018 Jul 12

Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.

Ann. Intern. Med., 2019 Oct 15

Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.

Arthritis care & research, 2012-05

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Medicine, 1976-05

Relapsing polychondritis: prospective study of 23 patients and a review of the literature.

Ann. Rheum. Dis., 2019 Sep 20

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.

Arthritis and rheumatism, 2010-01

Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.

J. Rheumatol., 2019 Sep 01

Malignancies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Population-based Cohort Study.

Ophthalmology, 2015-05

Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.

Retina,

LONG-TERM OUTCOMES OF RITUXIMAB THERAPY IN PATIENTS WITH NONINFECTIOUS POSTERIOR UVEITIS REFRACTORY TO CONVENTIONAL IMMUNOSUPPRESSIVE THERAPY.

Ophthalmic Res, 2018 Apr 10

Cyclophosphamide or Rituximab Treatment of Scleritis and Uveitis for Patients with Granulomatosis with Polyangiitis.

Dev Ophthalmol, 2012 Apr 17

Rituximab for noninfectious uveitis.

Arthritis Rheumatol, 2019 Aug 12

Long-Term Outcome of Ustekinumab Therapy for Behçet's Disease.

American journal of ophthalmology, 2017-11

Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis.

JAMA, 2006-12-27

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Annals of the rheumatic diseases, 2019-10

EULAR recommendations for the management of antiphospholipid syndrome in adults.

Diagnosis and Management of the Antiphospholipid Syndrome.

Arthritis care & research, 2017-03

Rates of Serious Infections in HIV-Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases.

Clin Exp Dermatol, 2018 May 24

Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma.

Journal of spinal disorders, 2001-10

Cauda equina syndrome in ankylosing spondylitis (the CES-AS syndrome): meta-analysis of outcomes after medical and surgical treatments.

Arthritis Rheum,

Dramatic efficacy of infliximab in cauda equina syndrome complicating ankylosing spondylitis.

N Engl J Med,

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.

Annals of the rheumatic diseases, 2009-03

EULAR recommendations for the management of primary small and medium vessel vasculitis.

Eur J Rheumatol, 2017 Feb 23

Management of the temporomandibular joint in inflammatory arthritis: Involvement of surgical procedures.

Rev Bras Reumatol Engl Ed, 2016 Mar 16

What rheumatologists should know about orofacial manifestations of autoimmune rheumatic diseases.

Arthritis & rheumatology (Hoboken, N.J.), 2016-11

Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.

Annals of the rheumatic diseases, 2019-04

Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.

BJR Case Rep, 2018 Sep 08

A case of aortitis during cisplatin-based chemotherapy for cervical cancer.

Southern medical journal, 2016-11

Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus.

Annals of the rheumatic diseases, 2011-05

Lupus Atherosclerosis Prevention Study (LAPS).

Atherosclerosis, 2015 Aug 28

Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study.

Ann Intern Med, 2020 Sep 22

Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study.

Clinical immunology (Orlando, Fla.), 2019-09

Treatment of antiphospholipid syndrome beyond anticoagulation.

Seminars in arthritis and rheumatism, 2019-08

Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.

Clin Rheumatol, 2012 Nov 22

Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.

Ann Pharmacother,

Effect of hemodialysis on leflunomide plasma concentrations.

Curr Rheumatol Rep, 2020 Oct 16

Morbidity and Mortality of Large-Vessel Vasculitides.

Arthritis Care Res (Hoboken), 2016 Jan

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Osteoarthritis Cartilage, 2018 Mar 02

A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial.

Ann Rheum Dis, 2018 Oct 03

Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial.

Ann Rheum Dis, 2018 Dec 14

Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis.

Lancet, 2019 Nov 11

Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial.

JAMA ophthalmology, 2014-12

The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.

Can J Ophthalmol,

Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease.

J Am Acad Dermatol, 2016 Feb 03

The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.

N Engl J Med,

Trial of Tocilizumab in Giant-Cell Arteritis.

Lancet, 2016 Mar 04

Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.

N Engl J Med, 2020 Apr 29

Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.

JAMA network open, 2018-11-02

Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2008-10

Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature.

Clin Rheumatol, 2006 Dec 21

Blood, 2015 May 13

A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4).

Blood, 2009 Nov 06

Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura.

Rheumatol Int, 2020 Sep 18

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.

The Journal of rheumatology, 2009-12

Serum cardiac troponin T, but not troponin I, is elevated in idiopathic inflammatory myopathies.

Semin Arthritis Rheum, 2020 Jun

TNF-alpha inhibition for the treatment of cardiac sarcoidosis.

Intern Med, 2014 Dec 01

Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions.

J Am Heart Assoc, 2019 Sep 06

Long-Term Corticosteroid-Sparing Immunosuppression for Cardiac Sarcoidosis.

Clin Rheumatol, 2007 Mar 30

Cardiac sarcoidosis responding to monotherapy with infliximab.

Annals of the rheumatic diseases, 2017-04

International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials.

Arthritis Care Res (Hoboken), 2018 Aug

Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort.

Arthritis Care Res (Hoboken),

Measuring Outcomes in Psoriatic Arthritis.

Curr Rheumatol Rep,

Polymorphism of HLA-B27: 105 subtypes currently known.

Ann Rheum Dis, 2011 Jul 28

HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis.

The Journal of arthroplasty, 2008-02

Determining "true" leukocytosis in bloody joint aspiration.

Ann Rheum Dis,

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.

The journal of allergy and clinical immunology. In practice, 2017

Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review.

J Am Dent Assoc,

Measuring salivary flow: challenges and opportunities.

Arthritis Rheumatol, 2016 Oct 26

2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts.

Ann Rheum Dis, 2019 Oct 31

EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies.

Annals of the rheumatic diseases, 2011-10

Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.

Arthritis Rheum,

Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis.

J Rheumatol,

A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.

Ann Rheum Dis, 2008 Jul 14

Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.

Ann Rheum Dis, 2010 Nov 10

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.

N Engl J Med,

Clinical practice. Care of the asplenic patient.

Mediterr J Rheumatol, 2020 Jun 11

Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies.

Autoimmun Rev, 2019 Sep 11

Fast track algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern".

Clin Exp Rheumatol, 2020 Aug 26

Consensus-based evaluation of dermatoscopy versus nailfold videocapillaroscopy in Raynaud's phenomenon linking USA and Europe: a European League against Rheumatism study group on microcirculation in rheumatic diseases project.

Microvasc Res, 2016 Sep 07

Capillary density: An important parameter in nailfold capillaroscopy.

J Rheumatol, 2019 Aug 15

Nailfold Videocapillaroscopy in Systemic Sclerosis-related Pulmonary Arterial Hypertension: A Systematic Literature Review.

The British journal of dermatology, 2019-11

Utilization patterns and performance of commercial myositis autoantibody panels in routine clinical practice.

Front Med (Lausanne), 2021 Aug 10

Nailfold Capillaroscopy Abnormalities Correlate With Disease Activity in Adult Dermatomyositis.

Autoimmun Rev, 2022 Apr 12

Standardised interpretation of capillaroscopy in autoimmune idiopathic inflammatory myopathies: A structured review on behalf of the EULAR study group on microcirculation in Rheumatic Diseases.

Clin Rheumatol, 2014 Oct 17

Nailfold capillaroscopic changes in dermatomyositis and polymyositis.

Clin Rheumatol, 2019 Aug 22

Nailfold videocapillaroscopy alterations in dermatomyositis, antisynthetase syndrome, overlap myositis, and immune-mediated necrotizing myopathy.

Reumatologia, 2022 Feb 28

Nailfold capillaroscopy changes with disease activity in patients with inflammatory myositis including overlap myositis, pure dermatomyositis, and pure polymyositis.

Rheumatology (Oxford), 2022 Mar 14

Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD.

Journal of thrombosis and haemostasis : JTH, 2018-06-07

McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome.

Clin Infect Dis,

Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease.

The New England journal of medicine, 2017-05-18

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

Kidney international reports, 2018-03

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.

N Engl J Med, 2020 Feb 13

Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.

Rheumatology (Oxford),

A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.

Rheumatol Int, 2019 Apr 30

Indications for bone marrow examinations in rheumatology.

Clin Exp Rheumatol, 2012 Sep 25

Indications for bone marrow examination in autoimmune disorders with concurrent haematologic alterations.

Wien Klin Wochenschr,

[Rationale for bone marrow examination in patients with inflammatory rheumatic diseases].

N Engl J Med, 2020 Dec 10

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.

N Engl J Med, 2020 Dec 17

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.

Front Pharmacol, 2019 Mar 26

Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders.

Kidney international, 2019-01

A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.

J Rheumatol, 2006 Jul 01

Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares.

Semin Arthritis Rheum,

Treatment of severe neutropenia due to Felty's syndrome or systemic lupus erythematosus with granulocyte colony-stimulating factor.

Lancet Respir Med, 2020 Aug 28

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.

Rheumatology (Oxford), 2013 Feb 16

Magnetic resonance imaging of the sacroiliac joints in the early detection of spondyloarthritis: no added value of gadolinium compared with short tau inversion recovery sequence.

Ann Rheum Dis, 2005 Jan 13

Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences.

Ann Rheum Dis, 2016 Jan 14

Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group.

Ann Rheum Dis, 2014 Jan 22

Does spinal MRI add incremental diagnostic value to MRI of the sacroiliac joints alone in patients with non-radiographic axial spondyloarthritis?

Ann Rheum Dis, 2012 May 14

Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group.

Ann Rheum Dis, 2015 Aug 18

Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis?

N Engl J Med,

Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.

Lupus, 2008-08

Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report.

Arthritis Rheumatol, 2021 Aug 12

Predicting the Risk of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: A Chinese Systemic Lupus Erythematosus Treatment and Research Group Cohort Study.

The Journal of rheumatology, 2012-02

Association of vascular physical examination findings and arteriographic lesions in large vessel vasculitis.

J Rheumatol, 2014 Aug 15

Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis.

Ann Clin Lab Sci,

Serum 14-3-3η Could Improve the Diagnostic Rate of Rheumatoid Arthritis and Correlates to Disease Activity.

Pediatr Rheumatol Online J, 2021 Feb 16

Prevalence and significance of serum 14-3-3η in juvenile idiopathic arthritis.

Clin Rheumatol, 2020 Mar 23

Serum 14-3-3η protein is associated with clinical and serologic features of Sjögren's syndrome in patients with systemic lupus erythematosus: a cross-sectional analysis.

The American journal of medicine, 1984-01

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Arthritis Rheum,

Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.

Ann Rheum Dis, 2019 Aug 14

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.

Rheumatology (Oxford, England), 2011-12

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.

Nat Rev Neurol,

The nonsystemic vasculitic neuropathies.

Nat Rev Dis Primers, 2018 Aug 02

Cryoglobulinaemia.

Nature reviews. Rheumatology, 2018-05

Treatment in myositis.

Trials, 2017 Jun 15

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.

N Engl J Med, 2019 Sep 29

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Arthritis Rheumatol, 2021 Feb 03

Tocilizumab Prevents Progression of Early Systemic Sclerosis Associated Interstitial Lung Disease.

Best Pract Res Clin Rheumatol,

Adult inflammatory myopathies.

N Engl J Med, 2021 Feb 18

Avacopan for the Treatment of ANCA-Associated Vasculitis.

Rheumatology (Oxford), 2021 Jan 07

Dual-energy computed tomography versus ultrasound, alone or combined, for the diagnosis of gout: a prospective study of accuracy.

Clinical and experimental rheumatology, 2018

Update on imaging in gout: contrasting and comparing the role of dual-energy computed tomography to traditional diagnostic and monitoring techniques.

Cochrane Database Syst Rev, 2013 May 31

Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.

Arthritis Rheumatol, 2020 May

Effect of Therapy on Radiographic Progression in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis.

Int J Clin Pract, 2021 Mar 24

Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey.

Mod Rheumatol, 2021 Feb 09

QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine.

Heart Rhythm, 2020 Jun 28

Effects of hydroxychloroquine treatment on QT interval.

N Engl J Med, 2012 May 20

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.

Ann Rheum Dis,

Antiphospholipid antibodies and infections.

Lancet Rheumatol, 2021 Apr 06

Incident systemic rheumatic disease following COVID-19.

N Engl J Med, 2020 Nov 20

Covid-19-Associated Myopathy Caused by Type I Interferonopathy.

Rheumatology (Oxford),

Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.

Semin Arthritis Rheum,

Autoantibodies in systemic sclerosis.

Ann Rheum Dis, 2017 Mar 23

Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate.

J Heart Lung Transplant, 2021 Nov

Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.

Interact Cardiovasc Thorac Surg, 2015 Jan 07

Recurrent polymyositis-associated lung disease after lung transplantation.

The Journal of rheumatology, 2004-12

Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.

Clin Pharmacokinet,

Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Gut,

Impaired conversion of prednisone to prednisolone in patients with liver cirrhosis.

Blood,

Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.

Annals of the rheumatic diseases, 2009-06

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Arthritis Care Res (Hoboken), 2019 Oct

J Clin Rheumatol, 2021 Sep 23

Role of Intravenous Immunoglobulin in Necrotizing Autoimmune Myopathy.

The New England journal of medicine, 2015-10-22

Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy.

Rheumatol Int, 2019 Feb 18

Intravenous human immunoglobulin and/or methylprednisolone pulse therapies as a possible treat-to-target strategy in immune-mediated necrotizing myopathies.

Arthritis and rheumatism, 2001-12

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Arthritis Rheumatol, 2019 Dec 26

Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis.

Arthritis care & research, 2018-03

Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients.

J Clin Rheumatol, 2020 Sep 18

Association of Hydroxychloroquine use and Hemolytic Anemia in Patients With Low Levels of Glucose-6-Phosphate Dehydrogenase.

Cureus, 2020 Aug 02

A Study on the Relevance of Glucose-6-Phosphate Dehydrogenase Level Screening in Patients with Rheumatic Diseases Prior to Initiating Treatment With Hydroxychloroquine.

Gut, 1999-04

Linkage of Crohn's disease to the major histocompatibility complex region is detected by multiple non-parametric analyses.

Gut, 2012-12

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Annals of the rheumatic diseases, 2019-04

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.

Ann Rheum Dis, 2014 Mar 21

The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study.

J Immunother Cancer, 2021 Feb

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.

J Natl Compr Canc Netw,

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.

Ann Oncol,

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

J Immunother Cancer,

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.

J Immunother Cancer,

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis.

J Clin Oncol, 2021 Dec 20

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

The New England journal of medicine, 2003-10-16

Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

Lupus, 2007

Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus.

J Allergy Clin Immunol, 2020 May 22

Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype.

Nat Rev Rheumatol,

Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis.

J Med Food,

Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Int J Clin Pract, 2021 Apr 29

Curcumin and rheumatoid arthritis: A systematic review of literature.

Nutrients, 2020 Dec 11

Efficacy of Spice Supplementation in Rheumatoid Arthritis: A Systematic Literature Review.

Current rheumatology reports, 2009-10

Diffuse idiopathic skeletal hyperostosis: differentiation from ankylosing spondylitis.

Radiology,

Radiographic and pathologic features of spinal involvement in diffuse idiopathic skeletal hyperostosis (DISH).

Curr Rheumatol Rep, 2021 Jan 26

Diffuse Idiopathic Skeletal Hyperostosis (DISH) and a Possible Inflammatory Component.

Kidney international, 2009-12

A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis.

Clinical journal of the American Society of Nephrology : CJASN, 2010-07

Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study.

Journal of the American Society of Nephrology : JASN, 2010-08

Comparison of different measures of urinary protein excretion for prediction of renal events.

Ann Intern Med,

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

Ann Rheum Dis, 2011 Nov 29

Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.

Trends Mol Med, 2021 Jun 07

Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome.

Rheumatology (Oxford),

The management of Sjögren's syndrome: British Society for Rheumatology guideline scope.

Rheumatology (Oxford), 2019 Mar 05

Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma.

Chest, 2021 Feb

Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's.

Arthritis & rheumatology (Hoboken, N.J.), 2015-07

Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Arthritis Rheum,

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.

Lancet, 2021 May 07

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Ann Rheum Dis, 2016 Nov 09

Update of EULAR recommendations for the treatment of systemic sclerosis.

Arthritis Rheumatol, 2021 Mar 24

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission.

Respir Med, 2012 Apr 09

The treatment of pulmonary sarcoidosis.

Am J Respir Crit Care Med,

Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.

Arthritis Rheum,

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.

Autoimmunity reviews, 2009-02

The risk of ultraviolet radiation exposure from indoor lamps in lupus erythematosus.

Arthritis and rheumatism, 2013-07

Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio.

Arthritis Rheumatol, 2021 Mar 24

Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study.

Rev Med Interne, 2016 Oct 13

[Blood concentration of hydroxychloroquine in systemic lupus erythematosus care: Usefulness and limits].

Arthritis Care Res (Hoboken), 2021 Mar 30

Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.

JAMA Dermatol,

Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.

Mod Rheumatol, 2020 Sep 17

Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.

Ann Rheum Dis, 2014 Feb 13

The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort.

Ann Rheum Dis, 2019 Jan 04

Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis.

Ann Rheum Dis, 2014 Apr 16

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.

N Engl J Med, 2019 Dec 18

Trial of Anifrolumab in Active Systemic Lupus Erythematosus.

Seminars in arthritis and rheumatism, 2010-12

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Clin Exp Rheumatol, 2012 Oct 17

Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?

Inflamm Bowel Dis,

Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.

Am J Clin Dermatol,

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Arthritis Rheum,

Tuberculosis associated with therapy against tumor necrosis factor alpha.

Eur Heart J, 2015 Aug 29

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Eur Respir J, 2019 Jan 24

Diagnosis of pulmonary hypertension.

Arthritis Rheumatol, 2017 May

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Arthritis Rheumatol, 2021 May 24

American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1.

N Engl J Med, 2021 Aug 04

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.

Annals of internal medicine, 1994-06-15

How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis?

Front Neurol, 2019 Jun 06

Primary Angiitis of the Central Nervous System: New Potential Imaging Techniques and Biomarkers in Blood and Cerebrospinal Fluid.

Semin Hematol,

Epidemiology and risk factors for venous thrombosis.

Journal of the American Society of Nephrology : JASN, 1993-07

Reversible renal failure in the primary antiphospholipid syndrome--a report of two cases.

Arthritis and rheumatism, 2013-02

A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2014-02

Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation.

Lupus, 2018-03

Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease.

Lupus,

16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.

Arthritis Rheum,

Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.

Rheumatology (Oxford), 2021 May 18

Cognitive dysfunction and associated neuroimaging biomarkers in antiphospholipid syndrome: a systematic review.

Am J Transplant, 2013 Jun 13

Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes.

Curr Opin Rheumatol,

Retinal vasculitis.

Arthritis Rheum,

Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.

Rheumatology (Oxford),

Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study.

BMJ Open, 2019 May 05

Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts.

Rheumatol Int, 2021 Jan 29

Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review.

Best practice & research. Clinical anaesthesiology, 2014-06

Perioperative analgesia and the effects of dietary supplements.

The Journal of rheumatology, 2016-08

Patients with Systemic Lupus Erythematosus Have Increased Risk of Short-term Adverse Events after Total Hip Arthroplasty.

JCI Insight, 2021 Feb 08

Antineutrophil properties of natural gingerols in models of lupus.

Arthritis Rheumatol, 2021 Jun 01

Sjögren's Disease, Not Syndrome.

Adv Ther, 2018 Mar 20

Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview.

J Arthroplasty, 2017 Jun 19

Total Hip Arthroplasty Outcomes: An 18-Year Experience in a Single Center: Is Systemic Lupus Erythematosus a Potential Risk Factor for Adverse Outcomes?

Int J Mol Sci, 2020 Mar 04

Curcumin Attenuates Both Acute and Chronic Immune Nephritis.

Open Access Rheumatol, 2019 Jan 29

Sjögren's syndrome and systemic lupus erythematosus: links and risks.

Respirology, 2016 Dec 17

Anaesthetic management of sleep-disordered breathing in adults.

Thromb Res, 2021 Jun 25

Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study.

The New England journal of medicine, 2018-03-29

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.

Seminars in arthritis and rheumatism, 2012-06

Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis.

Arthritis Rheumatol, 2021 Jul 08

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.

Ann Rheum Dis, 2019 Jul 03

2018 Update of the EULAR recommendations for the management of large vessel vasculitis.

Arthritis and rheumatism, 1992-08

Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial.

Arthritis and rheumatism, 1995-12

Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2001

Polyarteritis nodosa: spectrum of angiographic findings.

International journal of clinical rheumatology, 2010

Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management.

Rheumatology (Oxford),

Five successful pregnancies with antenatal anakinra exposure.

Z Rheumatol,

[IL-1-blockade with Anakinra during pregnancy : Retrospective analysis of efficacy and safety in female patients with familial Mediterranean fever].

Lupus, 2013-07

Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity.

Arthritis care & research, 2019-07

Area-Level Predictors of Medication Nonadherence Among US Medicaid Beneficiaries With Lupus: A Multilevel Study.

Arthritis care & research, 2019-11

Azathioprine and Mycophenolate Mofetil Adherence Patterns and Predictors Among Medicaid Beneficiaries With Systemic Lupus Erythematosus.

J Rheumatol,

Flares in lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone.

Lupus Sci Med, 2018 May 14

Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort.

Lupus Sci Med,

Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme.

Lupus, 2015 Jul 10

Colchicine: a simple and effective treatment for pericarditis in systemic lupus erythematosus? A report of 10 cases.

Mayo Clin Proc,

My Treatment Approach to Giant Cell Arteritis.

Lancet Haematol,

Management of anticoagulant-refractory thrombotic antiphospholipid syndrome.

Journal of neurovirology, 2018-06

Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.

Lupus science & medicine, 2014

Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements.

The Journal of rheumatology, 2015-11

Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.

Ophthalmology, 2016-06

Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).

Lupus science & medicine, 2017

Cell-bound complement activation products in SLE.

Journal of immunology research, 2017

Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus.

Lupus science & medicine, 2018

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.

Clin Pharmacol Ther, 2018 Jun

A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires.

Lupus Sci Med, 2016

Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus.

Lupus Sci Med, 2016 Feb 01

Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.

Lupus Sci Med,

A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus.

ACR Open Rheumatol, 2020 Oct 12

Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP).

Arthritis Rheumatol, 2021 May 02

Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.

Ann Rheum Dis, 2012 Nov 10

Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).

Arthritis Rheum,

Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.

Lupus,

Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis.

Arthritis Rheumatol, 2020 Jan 07

Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.

Lancet (London, England), 2015-09-19

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.

Annals of the rheumatic diseases, 2012-08

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

Brain : a journal of neurology, 2016-05

Association of inclusion body myositis with T cell large granular lymphocytic leukaemia.

Scand J Rheumatol, 2018 May 18

Blood-flow restricted resistance training in patients with sporadic inclusion body myositis: a randomized controlled trial.

Lupus Sci Med, 2019

Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery.

Arthritis care & research, 2019-11

Correlation of the Multi-Biomarker Disease Activity Score With Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis.

Arthritis Care Res (Hoboken), 2019 Dec

2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures.

Int J Rheum Dis, 2020 Sep 10

Diagnostic accuracy of 14-3-3 η protein in rheumatoid arthritis: A meta-analysis.

J Rheumatol, 2015 Jul 15

14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis.

Arthritis care & research, 2018-10

Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients With Breast Cancer.

Seminars in respiratory and critical care medicine, 2002-12

Hepatic, splenic, and gastrointestinal involvement with sarcoidosis.

Clinics in liver disease, 2019-05

Sarcoidosis and the Liver.

Eur J Gastroenterol Hepatol,

Natural history of hepatic sarcoidosis and its response to treatment.

Neth J Med,

Sarcoidosis of the liver: to treat or not to treat?

Semin Respir Crit Care Med, 2020 Aug 10

Hepatic Sarcoidosis: Current Concepts and Treatments.

J Rheumatol, 2019 Apr 01

Therapy with Biologic Agents After Diagnosis of Solid Malignancies: Results from the Corrona Registry.

RMD Open,

How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers.

Seminars in arthritis and rheumatism, 2016-02

Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature.

Bull Soc Ophtalmol Fr,

[Uveal effusion syndrome secondary to orbital cellulitis].

Am J Hum Genet, 2021 Jan 7

Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study.

Ann Rheum Dis, 2021 Jul 02

Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis.

Clin Neurophysiol Pract, 2018 Apr 05

Nerve conduction studies and EMG in carpal tunnel syndrome: Do they add value?

N Engl J Med,

Bisphosphonate use and atypical fractures of the femoral shaft.

Current rheumatology reports, 2018-09-10

Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?

Nat Rev Cardiol, 2019 Jun 26

Role of aspirin in primary prevention of cardiovascular disease.

Seizure, 2020 Apr 26

Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: A prospective cohort study.

The European respiratory journal, 2014-11

Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.

Clin Exp Rheumatol, 2019 Nov 20

Use of third-line therapies in advanced sarcoidosis.

N Engl J Med,

Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis.

Lung, 2021 Apr 07

Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study.

QJM, 2013 May 21

Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility.

Arthritis Rheumatol, 2021 Apr 01

Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.

Curr Med Chem,

Targeting IL-17 and IL-23 in Immune Mediated Renal Disease.

Pathology, 2017 Mar 11

The role of interleukin-17A in the pathogenesis of kidney diseases.

Lancet,

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.

Rheumatol Ther, 2021 Mar 21

Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade.

The American journal of medicine, 1996-07

End-stage renal disease and systemic lupus erythematosus.

BMC Nephrol, 2020 Oct 28

Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease.

Arthritis Rheum,

Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome.

Thromb Haemost, 2020 Jul 21

Is There an Additional Value in Detecting Anticardiolipin and Anti-β2 glycoprotein I IgA Antibodies in the Antiphospholipid Syndrome?

Arthritis & rheumatology (Hoboken, N.J.), 2016-01

Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.

Ann Rheum Dis, 2021 May 28

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.

RMD Open,

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis.

Arthritis Care Res (Hoboken), 2019 Nov 29

Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study.

Semin Arthritis Rheum, 2008 Dec 31

The risk of infections with biologic therapies for rheumatoid arthritis.

Ann Intern Med, 2021 Aug 31

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study.

Best practice & research. Clinical rheumatology, 2013-06

Cutaneous lupus erythematosus: diagnosis and treatment.

Dermatol Ther, 2016 Apr 12

Review of treatment for discoid lupus erythematosus.

Lancet, 2020 Nov 09

Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.

RMD Open, 2021 Sep

Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.

Lancet Oncol., 2013-10-01

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

The Journal of rheumatology, 1992-02

Antibiotic allergy in systemic lupus erythematosus: a case-control study.

The British journal of dermatology, 2011-03

A systematic review of drug-induced subacute cutaneous lupus erythematosus.

Current opinion in rheumatology, 2018-09

Drug-induced lupus erythematosus: an update on drugs and mechanisms.

Lupus, 2014 Feb 20

Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced.

Ann Rheum Dis, 2019 Feb 04

Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database.

Br J Dermatol, 2011 Jul 11

Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart.

Mod Rheumatol, 2016 Feb 17

Safety and efficacy of upfront graded administration of trimethoprim-sulfamethoxazole in systemic lupus erythematosus: A retrospective cohort study.

Annals of the rheumatic diseases, 2015-06

Rituximab for IgG4-related disease: a prospective, open-label trial.

J Immunother Cancer,

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.

BMJ open, 2019-03-20

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.

J Inflamm Res, 2020 Sep 14

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data.

Arthritis Rheumatol, 2017 Apr 07

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.

The Journal of rheumatology, 2013-05

Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study.

Current rheumatology reports, 2015-10

Myositis Mimics.

Curr Opin Rheumatol,

Myositis mimics: how to recognize them.

Autoimmun Rev, 2017 Sep 09

Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?

Neth J Med,

The treatment outcomes in IgG4-related disease.

Medicine (Baltimore),

Therapeutic approach to IgG4-related disease: A systematic review.

Lupus, 2013-02

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.

Arthritis Care Res (Hoboken), 2021 Jul

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Clin Liver Dis (Hoboken), 2018 Aug 22

Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance.

Ann Rheum Dis, 2016 Oct 03

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.

N Engl J Med,

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.

Arthritis Rheumatol, 2021 Mar 24

Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.

J Dermatol,

Cutaneous polyarteritis nodosa: a clinical and histopathological study of 20 cases.

Arthritis Rheum,

Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis.

Drugs,

Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.

Eur Respir J, 2021 Dec 16

ERS clinical practice guidelines on treatment of sarcoidosis.

Archives of internal medicine, 2004

Diagnostic accuracy for lupus and other systemic autoimmune diseases in the community setting.

ACR Open Rheumatol, 2021 Aug 25

Performance of Cytokine Storm Syndrome Scoring Systems in Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children.

Muscle & nerve, 2007-01

Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.

Annals of neurology, 1990-03

Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren's syndrome.

Rheum Dis Clin North Am, 2017 Aug 23

Neurologic Manifestations of Primary Sjögren Syndrome.

Neurology,

Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren's syndrome. IV immunoglobulin.

Medicine (Baltimore),

Sjögren Sensory Neuronopathy (Sjögren Ganglionopathy): Long-Term Outcome and Treatment Response in a Series of 13 Cases.

Muscle Nerve, 2014 Dec 23

Sensory ganglionopathy with livedoid vasculopathy controlled by immunotherapy.

The European respiratory journal, 2015-10

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.

Arthritis Res Ther, 2021 Mar 22

Vision loss in patients with giant cell arteritis treated with tocilizumab.

Pediatric blood & cancer, 2014-01

The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study.

Pediatric nephrology (Berlin, Germany), 2015-07

Fertility preservation in patients receiving cyclophosphamide therapy for renal disease.

Arthritis Rheumatol, 2020 Apr

2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.

Fertil Steril, 2016 Aug 10

Fertility counseling and preservation practices in youth with lupus and vasculitis undergoing gonadotoxic therapy.

Arthritis Care Res (Hoboken), 2020 May 19

Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis.

J Rheumatol, 2021 Feb 15

Real-world Risk of Relapse of Giant Cell Arteritis Treated With Tocilizumab: A Retrospective Analysis of 43 Patients.

Rheumatology (Oxford),

Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis.

The European respiratory journal, 2019-01

Risk stratification and medical therapy of pulmonary arterial hypertension.

Eur Respir J, 2019 Jan 24

Pulmonary hypertension in chronic lung disease and hypoxia.

Minerva Gastroenterol Dietol, 2016 Sep 07

Glutathione in the treatment of liver diseases: insights from clinical practice.

Free Radic Biol Med,

Effect of liver cirrhosis and age on the glutathione concentration in the plasma, erythrocytes, and gastric mucosa of man.

Ann Rheum Dis, 2017 Dec

2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.

Arthritis Care Res (Hoboken), 2019 Jan

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

The Journal of bone and joint surgery. American volume, 2018-04-18

Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain: A Double-Blinded, Randomized, Placebo-Controlled, Multinational Study.

Advances in therapy, 2019-06

Efficacy of Triamcinolone Acetonide Extended-Release in Participants with Unilateral Knee Osteoarthritis: A Post Hoc Analysis.

Osteoarthritis Cartilage, 2017 Oct 09

Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA).

J Bone Joint Surg Am,

An intra-articular, extended-release formulation of triamcinolone acetonide prolongs and amplifies analgesic effect in patients with osteoarthritis of the knee: a randomized clinical trial.

J Rheumatol, 2017 Dec 01

Short-term Repeat Magnetic Resonance Imaging Scans in Suspected Early Axial Spondyloarthritis Are Clinically Relevant Only in HLA-B27-positive Male Subjects.

Arthritis Rheumatol, 2019 Feb 06

Is it Useful to Repeat Magnetic Resonance Imaging of the Sacroiliac Joints After Three Months or One Year in the Diagnosis of Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis?

Arthritis Rheum,

Ten years' experience with needle biopsy in the early diagnosis of sacroiliitis.

Trials, 2021 Nov 15

Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial.

Arthritis Rheumatol, 2022 Feb 07

Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.

Lupus, 2021 May 27

16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome.

Eur J Dermatol,

Response of recalcitrant generalized morphea to intravenous immunoglobulins (IVIg): three cases and a review of the literature.

Rheum Dis Clin North Am, 2020 Aug

Risk Factors and Cancer Screening in Myositis.

Rheumatology (Oxford),

A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies.

J Orthop Translat, 2020 Jan 06

Guidelines for clinical diagnosis and treatment of osteonecrosis of the femoral head in adults (2019 version).

Curr Cardiol Rep, 2021 Jul 28

Autoimmune and Autoinflammatory Pericarditis: Definitions and New Treatments.

Clin Exp Rheumatol, 2013 Aug 02

New insights in the pathogenesis and therapy of idiopathic recurrent pericarditis in children.

Frontiers in immunology, 2019

Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies.

J Am Acad Dermatol, 2020 Sep 04

Accuracy of commercial panels to evaluate myositis autoantibodies: A single-institution perspective.

Rheumatology (Oxford),

The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity.

J Immunother Cancer,

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.

Case reports in rheumatology, 2017

A Rare Case of Digital Ischemia and Gangrene in ANCA-Associated Vasculitis with Review of the Literature.

Arch Dermatol,

Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.

Lupus, 2017 Sep 01

Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus.

Lupus, 2016 May 27

Cutaneous lupus erythematosus and systemic lupus erythematosus are associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.

Br J Dermatol, 2019 Apr 07

Validation and reliability of a disease-specific quality-of-life measure in patients with cutaneous lupus erythematosus.

Lupus, 2020 Apr 21

Current opinion on hydroxychloroquine-related retinal toxicity screening: where do we stand now?

Rheumatology (Oxford, England), 2017-06-01

A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies.

Autoimmun Rev, 2012 Jul 05

Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity.

Arthritis Rheum,

Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.

The New England journal of medicine, 2006-02-23

Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.

Arthritis and rheumatism, 2008-10

The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial.

Rheumatic diseases clinics of North America, 2011-02

Glucosamine and chondroitin sulfate.

Ann Rheum Dis, 2014 Jan 06

Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens.

Ann Rheum Dis, 2022 Mar 25

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.

Lupus science & medicine, 2018

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE.

Arthritis & rheumatology (Hoboken, N.J.), 2017-03

Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Rheumatology

Questions discussed in this category

Papers discussed in this category

Related Topics